{
  "doc_id": "30",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "磺脲类药物临床应用专家共识(2016年版)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物临床应用专家共识(2016年版)",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "2",
      "paragraph": "1 磺脲类药物的临床地位和使用时机",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1 磺脲类药物的临床地位和使用时机",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "3",
      "paragraph": "1.1 国内外指南如何推荐使用磺脲类药物? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.1 国内外指南如何推荐使用磺脲类药物? ",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T2",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 20
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "4",
      "paragraph": "尽管近年来新型降糖药物不断问世，但磺脲类药物因临床应用时间长、疗效确切，仍被多个国内外成人T2DM防治指南推荐为一线备选或二线降糖用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "尽管近年来新型降糖药物不断问世，但磺脲类药物因临床应用时间长、疗效确切，仍被多个国内外成人T2DM防治指南推荐为一线备选或二线降糖用药。",
          "start_idx": 0,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T3",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 22
            },
            {
              "entity_id": "T4",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 45,
              "end_idx": 47
            },
            {
              "entity_id": "T5",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 49
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R0",
              "head_entity_id": "T3",
              "tail_entity_id": "T5"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R1",
              "head_entity_id": "T4",
              "tail_entity_id": "T5"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "6",
      "paragraph": "1.2 哪些情况下磺脲类药物可以作为治疗T2DM的一线选择?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.2 哪些情况下磺脲类药物可以作为治疗T2DM的一线选择?",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T6",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14
            },
            {
              "entity_id": "T7",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 20,
              "end_idx": 22
            },
            {
              "entity_id": "T8",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 24
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R2",
              "head_entity_id": "T7",
              "tail_entity_id": "T8"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "7",
      "paragraph": "中国大规模横断面调查研究发现，口服降糖药治疗仍是治疗T2DM的主要降糖方案。虽然二甲双胍被多数指南推荐为治疗T2DM的一线用药，但对于二甲双胍不耐受或存在禁忌证的患者，可以考虑将磺脲类药物作为一线用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中国大规模横断面调查研究发现，口服降糖药治疗仍是治疗T2DM的主要降糖方案。虽然二甲双胍被多数指南推荐为治疗T2DM的一线用药，但对于二甲双胍不耐受或存在禁忌证的患者，可以考虑将磺脲类药物作为一线用药。",
          "start_idx": 0,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T9",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 15,
              "end_idx": 17
            },
            {
              "entity_id": "T10",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 71
            },
            {
              "entity_id": "T11",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44
            },
            {
              "entity_id": "T12",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 94
            },
            {
              "entity_id": "T13",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T14",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 30
            },
            {
              "entity_id": "T15",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 54,
              "end_idx": 56
            },
            {
              "entity_id": "T16",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 58
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R3",
              "head_entity_id": "T11",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R4",
              "head_entity_id": "T13",
              "tail_entity_id": "T14"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R5",
              "head_entity_id": "T15",
              "tail_entity_id": "T16"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "8",
      "paragraph": "对于新诊断的糖化血红蛋白(hemoglobin A1c，HbA1c)>7.5%的T2DM患者，可以选择作用机制互补的两种降糖药物联合应用。结合中国国情和中国T2DM患者的特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于新诊断的糖化血红蛋白(hemoglobin A1c，HbA1c)>7.5%的T2DM患者，可以选择作用机制互补的两种降糖药物联合应用。结合中国国情和中国T2DM患者的特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。",
          "start_idx": 0,
          "end_idx": 112,
          "entities": [
            {
              "entity_id": "T17",
              "entity": "糖化血红蛋白(hemoglobin A1c，HbA1c)",
              "entity_type": "Test_items",
              "start_idx": 6,
              "end_idx": 34
            },
            {
              "entity_id": "T18",
              "entity": ">7.5%",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 39
            },
            {
              "entity_id": "T19",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 88,
              "end_idx": 93
            },
            {
              "entity_id": "T20",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T21",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 40,
              "end_idx": 42
            },
            {
              "entity_id": "T22",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 44
            },
            {
              "entity_id": "T23",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 78,
              "end_idx": 80
            },
            {
              "entity_id": "T24",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 82
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R6",
              "head_entity_id": "T17",
              "tail_entity_id": "T22"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R7",
              "head_entity_id": "T19",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R8",
              "head_entity_id": "T20",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R9",
              "head_entity_id": "T21",
              "tail_entity_id": "T22"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R10",
              "head_entity_id": "T23",
              "tail_entity_id": "T24"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "9",
      "paragraph": "1.3 磺脲类药物可否用于超重或肥胖的T2DM患者? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.3 磺脲类药物可否用于超重或肥胖的T2DM患者? ",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T25",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T26",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 15
            },
            {
              "entity_id": "T27",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 18
            },
            {
              "entity_id": "T28",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 19,
              "end_idx": 21
            },
            {
              "entity_id": "T29",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 23
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R11",
              "head_entity_id": "T25",
              "tail_entity_id": "T29"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R12",
              "head_entity_id": "T28",
              "tail_entity_id": "T29"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "10",
      "paragraph": "磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。不同磺脲类药物单药治疗对患者体重的影响存在差异，改良剂型对患者体重的影响较小。临床研究显示，传统磺脲类药物(如氯磺丙脲、格列本脲)对肥胖患者体重影响较大，治疗3年平均约增加3~5kg；新的品种(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小(平均增加0.4~0.6kg)。由于二甲双胍、阿卡波糖、钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂等具有减轻体重的作用，对于超重或肥胖患者，磺脲类药物与此类药物联合使用，可减少磺脲类药物带来的体重增加的风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。不同磺脲类药物单药治疗对患者体重的影响存在差异，改良剂型对患者体重的影响较小。临床研究显示，传统磺脲类药物(如氯磺丙脲、格列本脲)对肥胖患者体重影响较大，治疗3年平均约增加3~5kg；新的品种(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小(平均增加0.4~0.6kg)。由于二甲双胍、阿卡波糖、钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂等具有减轻体重的作用，对于超重或肥胖患者，磺脲类药物与此类药物联合使用，可减少磺脲类药物带来的体重增加的风险。",
          "start_idx": 0,
          "end_idx": 295,
          "entities": [
            {
              "entity_id": "T30",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T31",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 39
            },
            {
              "entity_id": "T32",
              "entity": "传统磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 85
            },
            {
              "entity_id": "T33",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 87,
              "end_idx": 91
            },
            {
              "entity_id": "T34",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 92,
              "end_idx": 96
            },
            {
              "entity_id": "T35",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134
            },
            {
              "entity_id": "T36",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 140,
              "end_idx": 147
            },
            {
              "entity_id": "T37",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 175,
              "end_idx": 179
            },
            {
              "entity_id": "T38",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 184
            },
            {
              "entity_id": "T39",
              "entity": "钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 185,
              "end_idx": 240
            },
            {
              "entity_id": "T40",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 261,
              "end_idx": 266
            },
            {
              "entity_id": "T41",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 284
            },
            {
              "entity_id": "T42",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 18
            },
            {
              "entity_id": "T43",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 21
            },
            {
              "entity_id": "T44",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 100
            },
            {
              "entity_id": "T45",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 253,
              "end_idx": 255
            },
            {
              "entity_id": "T46",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 256,
              "end_idx": 258
            },
            {
              "entity_id": "T47",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T48",
              "entity": "减轻体重",
              "entity_type": "ADE",
              "start_idx": 243,
              "end_idx": 247
            },
            {
              "entity_id": "T49",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 287,
              "end_idx": 291
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R13",
              "head_entity_id": "T47",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R14",
              "head_entity_id": "T48",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R15",
              "head_entity_id": "T48",
              "tail_entity_id": "T38"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R16",
              "head_entity_id": "T48",
              "tail_entity_id": "T39"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R17",
              "head_entity_id": "T49",
              "tail_entity_id": "T41"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "11",
      "paragraph": "2 作用机制",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2 作用机制",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "12",
      "paragraph": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，包括依赖KATP通道和不依赖KAT P通道刺激胰岛β细胞分泌胰岛素。格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。②部分胰岛素增敏作用。人体葡萄糖钳夹试验表明，磺脲类药物可使外周葡萄糖利用率增加10%~52%(平均29%)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，包括依赖KATP通道和不依赖KAT P通道刺激胰岛β细胞分泌胰岛素。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T50",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T51",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R18",
              "head_entity_id": "T50",
              "tail_entity_id": "T51"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。",
          "start_idx": 64,
          "end_idx": 88,
          "entities": [
            {
              "entity_id": "T52",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "②部分胰岛素增敏作用。",
          "start_idx": 88,
          "end_idx": 99,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "人体葡萄糖钳夹试验表明，磺脲类药物可使外周葡萄糖利用率增加10%~52%(平均29%)。",
          "start_idx": 99,
          "end_idx": 143,
          "entities": [
            {
              "entity_id": "T53",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "13",
      "paragraph": "3 临床疗效",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3 临床疗效",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "14",
      "paragraph": "磺脲类药物单药治疗可使HbA1c下降1%~2%，降糖作用在常规剂量内呈剂量依赖性，且患者基线HbA1c越高，HbA1c降幅越大。磺脲类药物可以与多种其他降糖药物联合应用，并且可以作为治疗方案的基础用药之一长期使用。长期使用磺脲类药物治疗的患者应严密监测有无低血糖和体重增加。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物单药治疗可使HbA1c下降1%~2%，降糖作用在常规剂量内呈剂量依赖性，且患者基线HbA1c越高，HbA1c降幅越大。磺脲类药物可以与多种其他降糖药物联合应用，并且可以作为治疗方案的基础用药之一长期使用。长期使用磺脲类药物治疗的患者应严密监测有无低血糖和体重增加。",
          "start_idx": 0,
          "end_idx": 137,
          "entities": [
            {
              "entity_id": "T54",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T55",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 69
            },
            {
              "entity_id": "T56",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 116
            },
            {
              "entity_id": "T57",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 16
            },
            {
              "entity_id": "T58",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 51
            },
            {
              "entity_id": "T59",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 59
            },
            {
              "entity_id": "T60",
              "entity": "下降1%~2%",
              "entity_type": "Test_Value",
              "start_idx": 16,
              "end_idx": 23
            },
            {
              "entity_id": "T61",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 128,
              "end_idx": 131
            },
            {
              "entity_id": "T62",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 132,
              "end_idx": 136
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R19",
              "head_entity_id": "T61",
              "tail_entity_id": "T56"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R20",
              "head_entity_id": "T62",
              "tail_entity_id": "T56"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "15",
      "paragraph": "应用磺脲类药物治疗的患者需要有一定的胰岛功能。糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物治疗可能具有更好的疗效。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "应用磺脲类药物治疗的患者需要有一定的胰岛功能。糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物治疗可能具有更好的疗效。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T63",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T64",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T65",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 52
            },
            {
              "entity_id": "T66",
              "entity": "饮食和运动干预",
              "entity_type": "Treatment",
              "start_idx": 35,
              "end_idx": 42
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R21",
              "head_entity_id": "T65",
              "tail_entity_id": "T64"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R22",
              "head_entity_id": "T66",
              "tail_entity_id": "T64"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "16",
      "paragraph": "3.1 目前常用的磺脲类药物有哪些?如何调整剂量? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.1 目前常用的磺脲类药物有哪些?如何调整剂量? ",
          "start_idx": 0,
          "end_idx": 26,
          "entities": [
            {
              "entity_id": "T67",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "17",
      "paragraph": "早期的磺脲类药物以甲苯磺丁脲和氯磺丙脲为代表，由于甲苯磺丁脲增加T2DM患者心血管事件的发生风险，氯磺丙脲作用时间过长易导致低血糖等原因，临床上已基本淘汰。新一代磺脲类药物具有降糖作用强、不良反应少等优势，包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲(易导致低血糖临床较少使用)等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "早期的磺脲类药物以甲苯磺丁脲和氯磺丙脲为代表，由于甲苯磺丁脲增加T2DM患者心血管事件的发生风险，氯磺丙脲作用时间过长易导致低血糖等原因，临床上已基本淘汰。新一代磺脲类药物具有降糖作用强、不良反应少等优势，包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲(易导致低血糖临床较少使用)等。",
          "start_idx": 0,
          "end_idx": 145,
          "entities": [
            {
              "entity_id": "T68",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 8
            },
            {
              "entity_id": "T69",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14
            },
            {
              "entity_id": "T70",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T71",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 30
            },
            {
              "entity_id": "T72",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T73",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 81,
              "end_idx": 86
            },
            {
              "entity_id": "T74",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 105,
              "end_idx": 109
            },
            {
              "entity_id": "T75",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 110,
              "end_idx": 114
            },
            {
              "entity_id": "T76",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 119
            },
            {
              "entity_id": "T77",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 124
            },
            {
              "entity_id": "T78",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 129
            },
            {
              "entity_id": "T79",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34
            },
            {
              "entity_id": "T80",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36
            },
            {
              "entity_id": "T81",
              "entity": "心血管事件",
              "entity_type": "ADE",
              "start_idx": 38,
              "end_idx": 43
            },
            {
              "entity_id": "T82",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 62,
              "end_idx": 65
            },
            {
              "entity_id": "T83",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 133,
              "end_idx": 136
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R23",
              "head_entity_id": "T68",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R24",
              "head_entity_id": "T69",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R25",
              "head_entity_id": "T70",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R26",
              "head_entity_id": "T71",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R27",
              "head_entity_id": "T81",
              "tail_entity_id": "T71"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R28",
              "head_entity_id": "T82",
              "tail_entity_id": "T72"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R29",
              "head_entity_id": "T83",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R30",
              "head_entity_id": "T83",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R31",
              "head_entity_id": "T83",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R32",
              "head_entity_id": "T83",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R33",
              "head_entity_id": "T83",
              "tail_entity_id": "T78"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "18",
      "paragraph": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长。短效药物需要每日3次给药，中、长效药物每日给药1~2次即可。以餐后血糖升高为主的患者，宜选择短效制剂，以空腹血糖升高为主的患者或空腹、餐后血糖均高者，宜选择中、长效制剂。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长。短效药物需要每日3次给药，中、长效药物每日给药1~2次即可。",
          "start_idx": 0,
          "end_idx": 102,
          "entities": [
            {
              "entity_id": "T84",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T85",
              "entity": "格列吡嗪普通剂型",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 13
            },
            {
              "entity_id": "T86",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31
            },
            {
              "entity_id": "T87",
              "entity": "格列吡嗪控释剂",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 39
            },
            {
              "entity_id": "T88",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44
            },
            {
              "entity_id": "T89",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 52
            },
            {
              "entity_id": "T90",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T91",
              "entity": "每日3次",
              "entity_type": "Frequency",
              "start_idx": 78,
              "end_idx": 82
            },
            {
              "entity_id": "T92",
              "entity": "每日给药1~2次",
              "entity_type": "Frequency",
              "start_idx": 91,
              "end_idx": 99
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R34",
              "head_entity_id": "T91",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R35",
              "head_entity_id": "T91",
              "tail_entity_id": "T85"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R36",
              "head_entity_id": "T92",
              "tail_entity_id": "T86"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R37",
              "head_entity_id": "T92",
              "tail_entity_id": "T87"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R38",
              "head_entity_id": "T92",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R39",
              "head_entity_id": "T92",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R40",
              "head_entity_id": "T92",
              "tail_entity_id": "T90"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "以餐后血糖升高为主的患者，宜选择短效制剂，以空腹血糖升高为主的患者或空腹、餐后血糖均高者，宜选择中、长效制剂。",
          "start_idx": 102,
          "end_idx": 157,
          "entities": [
            {
              "entity_id": "T93",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 1,
              "end_idx": 5
            },
            {
              "entity_id": "T94",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 26
            },
            {
              "entity_id": "T95",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T96",
              "entity": "空腹、餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 34,
              "end_idx": 41
            },
            {
              "entity_id": "T97",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 5,
              "end_idx": 7
            },
            {
              "entity_id": "T98",
              "entity": "均高",
              "entity_type": "Test_Value",
              "start_idx": 41,
              "end_idx": 43
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "19",
      "paragraph": "低血糖是磺脲类药物治疗最常见的不良反应。为减少低血糖风险，服用磺脲类药物时宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。任何一种磺脲类药物的每日用量不应超过其最大剂量。常用磺脲类药物的用法、用量见表2。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "低血糖是磺脲类药物治疗最常见的不良反应。为减少低血糖风险，服用磺脲类药物时宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。",
          "start_idx": 0,
          "end_idx": 72,
          "entities": [
            {
              "entity_id": "T99",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T100",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 36
            },
            {
              "entity_id": "T103",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 0,
              "end_idx": 3
            },
            {
              "entity_id": "T104",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T105",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 49
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R41",
              "head_entity_id": "T103",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R42",
              "head_entity_id": "T104",
              "tail_entity_id": "T100"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "任何一种磺脲类药物的每日用量不应超过其最大剂量。",
          "start_idx": 72,
          "end_idx": 96,
          "entities": [
            {
              "entity_id": "T101",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "常用磺脲类药物的用法、用量见表2。",
          "start_idx": 96,
          "end_idx": 113,
          "entities": [
            {
              "entity_id": "T102",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "20",
      "paragraph": "3.2 磺脲类药物单药治疗疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.2 磺脲类药物单药治疗疗效如何? ",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T106",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "21",
      "paragraph": "磺脲类药物单药治疗一般可降低HbA1c1%~2%，平均降低1.5%。对于新诊断T2DM患者，格列齐特缓释片单药治疗52周可使HbA1c降低1.28%，安全性良好，治疗期间无严重低血糖事件发生；格列吡嗪控释片单药治疗8周可使HbA1c降低1.12%；格列本脲单药治疗12个月可使HbA1c降低1.26%；格列美脲单药治疗16周可使HbA1c降低2.5%，稳态模型评估的β细胞功能指数(HOMA-β)显著升高，稳态模型评估的胰岛素抵抗指数(HOMA-IR)显著降低，经血糖检测≤3.9mmol/L证实的低血糖发生率为3.8%，总体安全性良好。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物单药治疗一般可降低HbA1c1%~2%，平均降低1.5%。对于新诊断T2DM患者，格列齐特缓释片单药治疗52周可使HbA1c降低1.28%，安全性良好，治疗期间无严重低血糖事件发生；格列吡嗪控释片单药治疗8周可使HbA1c降低1.12%；格列本脲单药治疗12个月可使HbA1c降低1.26%；格列美脲单药治疗16周可使HbA1c降低2.5%，稳态模型评估的β细胞功能指数(HOMA-β)显著升高，稳态模型评估的胰岛素抵抗指数(HOMA-IR)显著降低，经血糖检测≤3.9mmol/L证实的低血糖发生率为3.8%，总体安全性良好。",
          "start_idx": 0,
          "end_idx": 269,
          "entities": [
            {
              "entity_id": "T107",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T108",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 53
            },
            {
              "entity_id": "T109",
              "entity": "格列吡嗪控释片",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 103
            },
            {
              "entity_id": "T110",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128
            },
            {
              "entity_id": "T111",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 155
            },
            {
              "entity_id": "T112",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 19
            },
            {
              "entity_id": "T113",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 67
            },
            {
              "entity_id": "T114",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 111,
              "end_idx": 116
            },
            {
              "entity_id": "T115",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 138,
              "end_idx": 143
            },
            {
              "entity_id": "T116",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 164,
              "end_idx": 169
            },
            {
              "entity_id": "T117",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 232,
              "end_idx": 234
            },
            {
              "entity_id": "T118",
              "entity": "1%~2%",
              "entity_type": "Test_Value",
              "start_idx": 19,
              "end_idx": 24
            },
            {
              "entity_id": "T119",
              "entity": "降低1.5%",
              "entity_type": "Test_Value",
              "start_idx": 27,
              "end_idx": 33
            },
            {
              "entity_id": "T120",
              "entity": "降低1.28%",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 74
            },
            {
              "entity_id": "T121",
              "entity": "降低1.12%",
              "entity_type": "Test_Value",
              "start_idx": 116,
              "end_idx": 123
            },
            {
              "entity_id": "T122",
              "entity": "降低1.26%",
              "entity_type": "Test_Value",
              "start_idx": 143,
              "end_idx": 150
            },
            {
              "entity_id": "T123",
              "entity": "降低2.5%",
              "entity_type": "Test_Value",
              "start_idx": 169,
              "end_idx": 175
            },
            {
              "entity_id": "T124",
              "entity": "≤3.9mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 236,
              "end_idx": 246
            },
            {
              "entity_id": "T125",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 39,
              "end_idx": 41
            },
            {
              "entity_id": "T126",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 43
            },
            {
              "entity_id": "T127",
              "entity": "52周",
              "entity_type": "Duration",
              "start_idx": 57,
              "end_idx": 60
            },
            {
              "entity_id": "T128",
              "entity": "8周",
              "entity_type": "Duration",
              "start_idx": 107,
              "end_idx": 109
            },
            {
              "entity_id": "T129",
              "entity": "12个月",
              "entity_type": "Duration",
              "start_idx": 132,
              "end_idx": 136
            },
            {
              "entity_id": "T130",
              "entity": "16周",
              "entity_type": "Duration",
              "start_idx": 159,
              "end_idx": 162
            },
            {
              "entity_id": "T131",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 88,
              "end_idx": 91
            },
            {
              "entity_id": "T132",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 86,
              "end_idx": 88
            },
            {
              "entity_id": "T133",
              "entity": "β细胞功能指数(HOMA-β)",
              "entity_type": "Test_items",
              "start_idx": 183,
              "end_idx": 198
            },
            {
              "entity_id": "T134",
              "entity": "显著升高",
              "entity_type": "Test_Value",
              "start_idx": 198,
              "end_idx": 202
            },
            {
              "entity_id": "T135",
              "entity": "胰岛素抵抗指数(HOMA-IR)",
              "entity_type": "Test_items",
              "start_idx": 210,
              "end_idx": 226
            },
            {
              "entity_id": "T136",
              "entity": "显著降低",
              "entity_type": "Test_Value",
              "start_idx": 226,
              "end_idx": 230
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R43",
              "head_entity_id": "T108",
              "tail_entity_id": "T126"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R44",
              "head_entity_id": "T131",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R45",
              "head_entity_id": "T127",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R46",
              "head_entity_id": "T128",
              "tail_entity_id": "T109"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R47",
              "head_entity_id": "T129",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R48",
              "head_entity_id": "T130",
              "tail_entity_id": "T111"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R49",
              "head_entity_id": "T125",
              "tail_entity_id": "T126"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "22",
      "paragraph": "3.3 磺脲类药物联合二甲双胍疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.3 磺脲类药物联合二甲双胍疗效如何? ",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T137",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T138",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "23",
      "paragraph": "磺脲类药物与二甲双胍联合治疗可同时改善胰岛素分泌不足和胰岛素抵抗，其疗效和安全性已得到长期临床验证，是推荐的联合治疗方案之一。一项系统性评价结果显示，磺脲类药物联合二甲双胍可使HbA1c降低0.47%~1.30%。与二甲双胍单药治疗相比，二甲双胍联合格列齐特或格列美脲治疗3个月均可使患者HbA1c降低1.9%。为期2年的随机对照研究结果显示，T2DM患者起始二甲双胍联合磺脲类药物治疗可降低HbA1c 1.5%；二甲双胍单药治疗血糖控制不佳的患者加用格列吡嗪治疗可使HbA1c进一步降低0.59%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物与二甲双胍联合治疗可同时改善胰岛素分泌不足和胰岛素抵抗，其疗效和安全性已得到长期临床验证，是推荐的联合治疗方案之一。一项系统性评价结果显示，磺脲类药物联合二甲双胍可使HbA1c降低0.47%~1.30%。与二甲双胍单药治疗相比，二甲双胍联合格列齐特或格列美脲治疗3个月均可使患者HbA1c降低1.9%。为期2年的随机对照研究结果显示，T2DM患者起始二甲双胍联合磺脲类药物治疗可降低HbA1c 1.5%；二甲双胍单药治疗血糖控制不佳的患者加用格列吡嗪治疗可使HbA1c进一步降低0.59%。",
          "start_idx": 0,
          "end_idx": 250,
          "entities": [
            {
              "entity_id": "T139",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T140",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T141",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 80
            },
            {
              "entity_id": "T142",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 82,
              "end_idx": 86
            },
            {
              "entity_id": "T143",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 112
            },
            {
              "entity_id": "T144",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123
            },
            {
              "entity_id": "T145",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 129
            },
            {
              "entity_id": "T146",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134
            },
            {
              "entity_id": "T147",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 184
            },
            {
              "entity_id": "T148",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 186,
              "end_idx": 191
            },
            {
              "entity_id": "T149",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 207,
              "end_idx": 211
            },
            {
              "entity_id": "T150",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 226,
              "end_idx": 230
            },
            {
              "entity_id": "T151",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 88,
              "end_idx": 93
            },
            {
              "entity_id": "T152",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 144,
              "end_idx": 149
            },
            {
              "entity_id": "T153",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 196,
              "end_idx": 201
            },
            {
              "entity_id": "T154",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 234,
              "end_idx": 239
            },
            {
              "entity_id": "T155",
              "entity": "降低0.47%~1.30%",
              "entity_type": "Test_Value",
              "start_idx": 93,
              "end_idx": 106
            },
            {
              "entity_id": "T156",
              "entity": "降低1.9%",
              "entity_type": "Test_Value",
              "start_idx": 149,
              "end_idx": 155
            },
            {
              "entity_id": "T157",
              "entity": "1.5%",
              "entity_type": "Test_Value",
              "start_idx": 202,
              "end_idx": 206
            },
            {
              "entity_id": "T158",
              "entity": "降低0.59%",
              "entity_type": "Test_Value",
              "start_idx": 242,
              "end_idx": 249
            },
            {
              "entity_id": "T159",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 172,
              "end_idx": 174
            },
            {
              "entity_id": "T160",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 172,
              "end_idx": 176
            },
            {
              "entity_id": "T161",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 215,
              "end_idx": 217
            },
            {
              "entity_id": "T162",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 217,
              "end_idx": 221
            },
            {
              "entity_id": "T163",
              "entity": "胰岛素分泌不足",
              "entity_type": "Pathogenesis",
              "start_idx": 19,
              "end_idx": 26
            },
            {
              "entity_id": "T164",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 27,
              "end_idx": 32
            },
            {
              "entity_id": "T165",
              "entity": "3个月",
              "entity_type": "Duration",
              "start_idx": 136,
              "end_idx": 139
            }
          ],
          "relations": [
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R50",
              "head_entity_id": "T165",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R51",
              "head_entity_id": "T165",
              "tail_entity_id": "T145"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R52",
              "head_entity_id": "T165",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T147",
              "tail_entity_id": "T160"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R54",
              "head_entity_id": "T148",
              "tail_entity_id": "T160"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R55",
              "head_entity_id": "T159",
              "tail_entity_id": "T160"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "24",
      "paragraph": "3.4 磺脲类药物联合α-糖苷酶抑制剂的疗效如何?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.4 磺脲类药物联合α-糖苷酶抑制剂的疗效如何?",
          "start_idx": 0,
          "end_idx": 25,
          "entities": [
            {
              "entity_id": "T166",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T167",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 19
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "25",
      "paragraph": "磺脲类药物促进胰岛素分泌，α-糖苷酶抑制剂抑制肠道碳水化合物吸收，二者联合，机制互补，可更好地控制T2DM患者的空腹血糖和餐后血糖。一项交叉设计临床对照研究，磺脲类药物联合阿卡波糖可使患者HbA1c下降2.2%，空腹血糖(fasting plasma glucose，FPG)下降2.8mmol/L，餐后血糖(postprandial plasma glucose，PPG)下降5.3mmol/L，甘油三酯下降35.7mg/dl。随机、双盲、安慰剂对照研究显示，与阿卡波糖、格列本脲单药治疗相比，格列本脲联合阿卡波糖可显著降低患者的餐后血糖，且较格列本脲单药治疗显著降低患者血清胰岛素水平。对于新诊断T2DM患者，格列吡嗪控释片联合阿卡波糖治疗8周较格列吡嗪控释片单药治疗，患者的体质指数(body mass index，BMI)、腰围及HbA1c变化无统计学差异，但前者可显著改善患者HOMA-IR，降低餐后血糖增量，且有效减少血糖波动(日间血糖变异度与日内血糖变异度)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物促进胰岛素分泌，α-糖苷酶抑制剂抑制肠道碳水化合物吸收，二者联合，机制互补，可更好地控制T2DM患者的空腹血糖和餐后血糖。一项交叉设计临床对照研究，磺脲类药物联合阿卡波糖可使患者HbA1c下降2.2%，空腹血糖(fasting plasma glucose，FPG)下降2.8mmol/L，餐后血糖(postprandial plasma glucose，PPG)下降5.3mmol/L，甘油三酯下降35.7mg/dl。随机、双盲、安慰剂对照研究显示，与阿卡波糖、格列本脲单药治疗相比，格列本脲联合阿卡波糖可显著降低患者的餐后血糖，且较格列本脲单药治疗显著降低患者血清胰岛素水平。对于新诊断T2DM患者，格列吡嗪控释片联合阿卡波糖治疗8周较格列吡嗪控释片单药治疗，患者的体质指数(body mass index，BMI)、腰围及HbA1c变化无统计学差异，但前者可显著改善患者HOMA-IR，降低餐后血糖增量，且有效减少血糖波动(日间血糖变异度与日内血糖变异度)。",
          "start_idx": 0,
          "end_idx": 437,
          "entities": [
            {
              "entity_id": "T168",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T169",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 21
            },
            {
              "entity_id": "T170",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 79,
              "end_idx": 84
            },
            {
              "entity_id": "T171",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 90
            },
            {
              "entity_id": "T172",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 232,
              "end_idx": 236
            },
            {
              "entity_id": "T173",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 237,
              "end_idx": 241
            },
            {
              "entity_id": "T174",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 248,
              "end_idx": 252
            },
            {
              "entity_id": "T175",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 254,
              "end_idx": 258
            },
            {
              "entity_id": "T176",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 273,
              "end_idx": 277
            },
            {
              "entity_id": "T177",
              "entity": "格列吡嗪控释片",
              "entity_type": "Drug",
              "start_idx": 307,
              "end_idx": 314
            },
            {
              "entity_id": "T178",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 316,
              "end_idx": 320
            },
            {
              "entity_id": "T179",
              "entity": "格列吡嗪控释片",
              "entity_type": "Drug",
              "start_idx": 325,
              "end_idx": 332
            },
            {
              "entity_id": "T180",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 49,
              "end_idx": 51
            },
            {
              "entity_id": "T181",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T182",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 56,
              "end_idx": 60
            },
            {
              "entity_id": "T183",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 65
            },
            {
              "entity_id": "T184",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 94,
              "end_idx": 99
            },
            {
              "entity_id": "T185",
              "entity": "空腹血糖(fasting plasma glucose，FPG)",
              "entity_type": "Test_items",
              "start_idx": 106,
              "end_idx": 138
            },
            {
              "entity_id": "T186",
              "entity": "餐后血糖(postprandial plasma glucose，PPG)",
              "entity_type": "Test_items",
              "start_idx": 150,
              "end_idx": 187
            },
            {
              "entity_id": "T187",
              "entity": "甘油三酯",
              "entity_type": "Test_items",
              "start_idx": 199,
              "end_idx": 203
            },
            {
              "entity_id": "T188",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 266,
              "end_idx": 270
            },
            {
              "entity_id": "T189",
              "entity": "血清胰岛素水平",
              "entity_type": "Test_items",
              "start_idx": 287,
              "end_idx": 294
            },
            {
              "entity_id": "T190",
              "entity": "体质指数(body mass index，BMI)",
              "entity_type": "Test_items",
              "start_idx": 340,
              "end_idx": 365
            },
            {
              "entity_id": "T191",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 369,
              "end_idx": 374
            },
            {
              "entity_id": "T192",
              "entity": "HOMA-IR",
              "entity_type": "Test_items",
              "start_idx": 393,
              "end_idx": 400
            },
            {
              "entity_id": "T193",
              "entity": "餐后血糖增量",
              "entity_type": "Test_items",
              "start_idx": 403,
              "end_idx": 409
            },
            {
              "entity_id": "T194",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 415,
              "end_idx": 417
            },
            {
              "entity_id": "T195",
              "entity": "日间血糖变异度",
              "entity_type": "Test_items",
              "start_idx": 420,
              "end_idx": 427
            },
            {
              "entity_id": "T196",
              "entity": "日内血糖变异度",
              "entity_type": "Test_items",
              "start_idx": 428,
              "end_idx": 435
            },
            {
              "entity_id": "T197",
              "entity": "下降2.2%",
              "entity_type": "Test_Value",
              "start_idx": 99,
              "end_idx": 105
            },
            {
              "entity_id": "T198",
              "entity": "下降2.8mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 138,
              "end_idx": 149
            },
            {
              "entity_id": "T199",
              "entity": "下降5.3mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 187,
              "end_idx": 198
            },
            {
              "entity_id": "T200",
              "entity": "下降35.7mg/dl",
              "entity_type": "Test_Value",
              "start_idx": 203,
              "end_idx": 214
            },
            {
              "entity_id": "T201",
              "entity": "8周",
              "entity_type": "Duration",
              "start_idx": 322,
              "end_idx": 324
            },
            {
              "entity_id": "T202",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 300,
              "end_idx": 302
            },
            {
              "entity_id": "T203",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 300,
              "end_idx": 304
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R56",
              "head_entity_id": "T168",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R57",
              "head_entity_id": "T169",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T177",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R59",
              "head_entity_id": "T201",
              "tail_entity_id": "T177"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R60",
              "head_entity_id": "T178",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R61",
              "head_entity_id": "T201",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R62",
              "head_entity_id": "T180",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R63",
              "head_entity_id": "T182",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R64",
              "head_entity_id": "T183",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R65",
              "head_entity_id": "T190",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R66",
              "head_entity_id": "T191",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R67",
              "head_entity_id": "T192",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R68",
              "head_entity_id": "T193",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R69",
              "head_entity_id": "T194",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R70",
              "head_entity_id": "T195",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R71",
              "head_entity_id": "T196",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R72",
              "head_entity_id": "T202",
              "tail_entity_id": "T203"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "26",
      "paragraph": "3.5 磺脲类药物联合噻唑烷二酮类药物的疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.5 磺脲类药物联合噻唑烷二酮类药物的疗效如何? ",
          "start_idx": 0,
          "end_idx": 26,
          "entities": [
            {
              "entity_id": "T204",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T205",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 19
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "27",
      "paragraph": "磺脲类药物单药治疗血糖控制不佳时，联合噻唑烷二酮类药物治疗可以进一步改善血糖，减轻胰岛素抵抗。随机、双盲、安慰剂对照研究结果显示，患者使用罗格列酮4mg联合磺脲类药物和罗格列酮8mg联合磺脲类药物治疗24周，HbA1c分别下降1.04%和1.44%，空腹血糖分别下降1.2mmol/L和2.0mmol/L，血中胰岛素水平较基线分别下降23.3pmol/L和30.4pmol/L，但患者体重增加更明显。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物单药治疗血糖控制不佳时，联合噻唑烷二酮类药物治疗可以进一步改善血糖，减轻胰岛素抵抗。随机、双盲、安慰剂对照研究结果显示，患者使用罗格列酮4mg联合磺脲类药物和罗格列酮8mg联合磺脲类药物治疗24周，HbA1c分别下降1.04%和1.44%，空腹血糖分别下降1.2mmol/L和2.0mmol/L，血中胰岛素水平较基线分别下降23.3pmol/L和30.4pmol/L，但患者体重增加更明显。",
          "start_idx": 0,
          "end_idx": 200,
          "entities": [
            {
              "entity_id": "T206",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T207",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 27
            },
            {
              "entity_id": "T208",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 73
            },
            {
              "entity_id": "T209",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 83
            },
            {
              "entity_id": "T210",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88
            },
            {
              "entity_id": "T211",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 98
            },
            {
              "entity_id": "T212",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 11
            },
            {
              "entity_id": "T213",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 38
            },
            {
              "entity_id": "T214",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 104,
              "end_idx": 109
            },
            {
              "entity_id": "T215",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 125,
              "end_idx": 129
            },
            {
              "entity_id": "T216",
              "entity": "血中胰岛素水平",
              "entity_type": "Test_items",
              "start_idx": 153,
              "end_idx": 160
            },
            {
              "entity_id": "T217",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T218",
              "entity": "分别下降1.04%和1.44%",
              "entity_type": "Test_Value",
              "start_idx": 109,
              "end_idx": 124
            },
            {
              "entity_id": "T219",
              "entity": "下降1.2mmol/L和2.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 131,
              "end_idx": 152
            },
            {
              "entity_id": "T220",
              "entity": "下降23.3pmol/L和30.4pmol/L",
              "entity_type": "Test_Value",
              "start_idx": 165,
              "end_idx": 188
            },
            {
              "entity_id": "T221",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 41,
              "end_idx": 46
            },
            {
              "entity_id": "T222",
              "entity": "4mg",
              "entity_type": "Amount",
              "start_idx": 73,
              "end_idx": 76
            },
            {
              "entity_id": "T223",
              "entity": "8mg",
              "entity_type": "Amount",
              "start_idx": 88,
              "end_idx": 91
            },
            {
              "entity_id": "T224",
              "entity": "24周",
              "entity_type": "Duration",
              "start_idx": 100,
              "end_idx": 103
            },
            {
              "entity_id": "T225",
              "entity": "体重增加更明显",
              "entity_type": "ADE",
              "start_idx": 192,
              "end_idx": 199
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R73",
              "head_entity_id": "T222",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R74",
              "head_entity_id": "T224",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R75",
              "head_entity_id": "T225",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R76",
              "head_entity_id": "T224",
              "tail_entity_id": "T209"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R77",
              "head_entity_id": "T225",
              "tail_entity_id": "T209"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R78",
              "head_entity_id": "T223",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R79",
              "head_entity_id": "T224",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R80",
              "head_entity_id": "T225",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R81",
              "head_entity_id": "T224",
              "tail_entity_id": "T211"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R82",
              "head_entity_id": "T225",
              "tail_entity_id": "T211"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "28",
      "paragraph": "3.6 磺脲类药物联合二肽基肽酶-4抑制剂的疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.6 磺脲类药物联合二肽基肽酶-4抑制剂的疗效如何? ",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T226",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T227",
              "entity": "二肽基肽酶-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 21
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "29",
      "paragraph": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂通过降低DPP-4酶的催化活性，抑制胰高血糖素样肽-1(glucagon-like peptide-1，GLP-1)降解，提升GLP-1在血液中的浓度，刺激胰岛素和抑制胰高血糖素分泌，从而达到控制血糖的目的。磺脲类药物单药治疗血糖控制不佳时，联合DPP-4抑制剂可更好地控制血糖。一项为期24周的多中心、随机、双盲、安慰剂对照研究结果显示，格列美脲联合维格列汀50mg/d或100mg/d不但有效降低患者的HbA1c水平，同时改善患者β细胞功能和餐后血糖水平，且对于年龄≥65岁的老年患者同样安全、有效。磺脲类药物联合DPP-4抑制剂会增加低血糖的发生风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂通过降低DPP-4酶的催化活性，抑制胰高血糖素样肽-1(glucagon-like peptide-1，GLP-1)降解，提升GLP-1在血液中的浓度，刺激胰岛素和抑制胰高血糖素分泌，从而达到控制血糖的目的。磺脲类药物单药治疗血糖控制不佳时，联合DPP-4抑制剂可更好地控制血糖。一项为期24周的多中心、随机、双盲、安慰剂对照研究结果显示，格列美脲联合维格列汀50mg/d或100mg/d不但有效降低患者的HbA1c水平，同时改善患者β细胞功能和餐后血糖水平，且对于年龄≥65岁的老年患者同样安全、有效。磺脲类药物联合DPP-4抑制剂会增加低血糖的发生风险。",
          "start_idx": 0,
          "end_idx": 319,
          "entities": [
            {
              "entity_id": "T228",
              "entity": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 40
            },
            {
              "entity_id": "T229",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 149
            },
            {
              "entity_id": "T230",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 171
            },
            {
              "entity_id": "T231",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 210,
              "end_idx": 214
            },
            {
              "entity_id": "T232",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 216,
              "end_idx": 220
            },
            {
              "entity_id": "T233",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 138,
              "end_idx": 140
            },
            {
              "entity_id": "T234",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 153,
              "end_idx": 155
            },
            {
              "entity_id": "T235",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 177,
              "end_idx": 179
            },
            {
              "entity_id": "T236",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 243,
              "end_idx": 248
            },
            {
              "entity_id": "T237",
              "entity": "餐后血糖水平",
              "entity_type": "Test_items",
              "start_idx": 263,
              "end_idx": 269
            },
            {
              "entity_id": "T238",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 292,
              "end_idx": 297
            },
            {
              "entity_id": "T239",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 299,
              "end_idx": 307
            },
            {
              "entity_id": "T240",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 310,
              "end_idx": 313
            },
            {
              "entity_id": "T241",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 155,
              "end_idx": 159
            },
            {
              "entity_id": "T242",
              "entity": "50mg/d",
              "entity_type": "Amount",
              "start_idx": 220,
              "end_idx": 226
            },
            {
              "entity_id": "T243",
              "entity": "100mg/d",
              "entity_type": "Amount",
              "start_idx": 227,
              "end_idx": 234
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R83",
              "head_entity_id": "T242",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R84",
              "head_entity_id": "T243",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R85",
              "head_entity_id": "T240",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R86",
              "head_entity_id": "T240",
              "tail_entity_id": "T239"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "30",
      "paragraph": "3.7 磺脲类药物联合SGLT-2抑制剂的疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.7 磺脲类药物联合SGLT-2抑制剂的疗效如何? ",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T244",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T245",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 20
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "31",
      "paragraph": "SGLT-2抑制剂通过抑制近端肾小管钠-葡萄糖重吸收、促进尿糖排泄降低血糖浓度。磺脲类药物联合SGLT-2抑制剂可进一步降低患者血糖，并减轻患者体重，但两者联用应注意低血糖风险。一项为期48周的随机、双盲、对照研究结果显示，格列美脲治疗血糖控制不佳的T2DM患者，联合使用达格列净(dapagliflozin)2.5mg/d、5mg/d、10mg/d后，HbA1c分别进一步下降0.41%、0.56%和0.73%，体重降幅分为1.36kg、1.54kg、2.41kg，低血糖发生率为9.7%~11.3%。一项为期24周随机双盲试验和28周开放标签延长期试验的研究结果显示，与安慰剂比较，鲁格列净(Luseogliflozin)联合磺脲类药物可进一步降低患者HbA1c0.63%，低血糖事件发生率为10.7%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂通过抑制近端肾小管钠-葡萄糖重吸收、促进尿糖排泄降低血糖浓度。磺脲类药物联合SGLT-2抑制剂可进一步降低患者血糖，并减轻患者体重，但两者联用应注意低血糖风险。一项为期48周的随机、双盲、对照研究结果显示，格列美脲治疗血糖控制不佳的T2DM患者，联合使用达格列净(dapagliflozin)2.5mg/d、5mg/d、10mg/d后，HbA1c分别进一步下降0.41%、0.56%和0.73%，体重降幅分为1.36kg、1.54kg、2.41kg，低血糖发生率为9.7%~11.3%。一项为期24周随机双盲试验和28周开放标签延长期试验的研究结果显示，与安慰剂比较，鲁格列净(Luseogliflozin)联合磺脲类药物可进一步降低患者HbA1c0.63%，低血糖事件发生率为10.7%。",
          "start_idx": 0,
          "end_idx": 354,
          "entities": [
            {
              "entity_id": "T246",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9
            },
            {
              "entity_id": "T247",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 45
            },
            {
              "entity_id": "T248",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 56
            },
            {
              "entity_id": "T249",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 116
            },
            {
              "entity_id": "T250",
              "entity": "达格列净(dapagliflozin)",
              "entity_type": "Drug",
              "start_idx": 136,
              "end_idx": 155
            },
            {
              "entity_id": "T251",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 315,
              "end_idx": 320
            },
            {
              "entity_id": "T252",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 37
            },
            {
              "entity_id": "T253",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 66
            },
            {
              "entity_id": "T254",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 118,
              "end_idx": 120
            },
            {
              "entity_id": "T255",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 177,
              "end_idx": 182
            },
            {
              "entity_id": "T256",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 328,
              "end_idx": 333
            },
            {
              "entity_id": "T257",
              "entity": "减轻患者体重",
              "entity_type": "ADE",
              "start_idx": 68,
              "end_idx": 74
            },
            {
              "entity_id": "T258",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 83,
              "end_idx": 86
            },
            {
              "entity_id": "T259",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 234,
              "end_idx": 237
            },
            {
              "entity_id": "T260",
              "entity": "鲁格列净(Luseogliflozin)",
              "entity_type": "Drug",
              "start_idx": 293,
              "end_idx": 313
            },
            {
              "entity_id": "T261",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 339,
              "end_idx": 342
            },
            {
              "entity_id": "T262",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 125,
              "end_idx": 127
            },
            {
              "entity_id": "T263",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 125,
              "end_idx": 129
            },
            {
              "entity_id": "T264",
              "entity": "2.5mg/d",
              "entity_type": "Amount",
              "start_idx": 155,
              "end_idx": 162
            },
            {
              "entity_id": "T265",
              "entity": "5mg/d",
              "entity_type": "Amount",
              "start_idx": 163,
              "end_idx": 168
            },
            {
              "entity_id": "T266",
              "entity": "10mg/d",
              "entity_type": "Amount",
              "start_idx": 169,
              "end_idx": 175
            },
            {
              "entity_id": "T267",
              "entity": "下降0.41%、0.56%和0.73%",
              "entity_type": "Test_Value",
              "start_idx": 187,
              "end_idx": 206
            },
            {
              "entity_id": "T268",
              "entity": "0.63%",
              "entity_type": "Test_Value",
              "start_idx": 333,
              "end_idx": 338
            },
            {
              "entity_id": "T269",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 120,
              "end_idx": 124
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R87",
              "head_entity_id": "T257",
              "tail_entity_id": "T247"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R88",
              "head_entity_id": "T258",
              "tail_entity_id": "T247"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R89",
              "head_entity_id": "T257",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R90",
              "head_entity_id": "T258",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R91",
              "head_entity_id": "T259",
              "tail_entity_id": "T249"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R92",
              "head_entity_id": "T249",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R93",
              "head_entity_id": "T264",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R94",
              "head_entity_id": "T265",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R95",
              "head_entity_id": "T266",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R96",
              "head_entity_id": "T259",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R97",
              "head_entity_id": "T250",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R98",
              "head_entity_id": "T261",
              "tail_entity_id": "T251"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R99",
              "head_entity_id": "T254",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R100",
              "head_entity_id": "T261",
              "tail_entity_id": "T260"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R101",
              "head_entity_id": "T262",
              "tail_entity_id": "T263"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "32",
      "paragraph": "3.8 磺脲类药物联合GLP-1受体激动剂的疗效如何?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.8 磺脲类药物联合GLP-1受体激动剂的疗效如何?",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T270",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T271",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 21
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "33",
      "paragraph": "GLP-1受体激动剂以葡萄糖浓度依赖的方式促进β细胞分泌胰岛素、降低α细胞分泌胰血高糖素，磺脲类药物联合GLP-1受体激动剂可使HbA1c水平显著降低，且安全耐受性良好。一项为期26周的随机、双盲、对照研究结果显示，无论之前患者接受何种治疗，格列美脲联合利拉鲁肽治疗均可快速降低HbA1c达1.1%，显著优于格列美脲单药治疗或格列美脲联合罗格列酮治疗。格列美脲联合利拉鲁肽1.8mg/d治疗组患者体重降低，<10%的患者发生轻度低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GLP-1受体激动剂以葡萄糖浓度依赖的方式促进β细胞分泌胰岛素、降低α细胞分泌胰血高糖素，磺脲类药物联合GLP-1受体激动剂可使HbA1c水平显著降低，且安全耐受性良好。一项为期26周的随机、双盲、对照研究结果显示，无论之前患者接受何种治疗，格列美脲联合利拉鲁肽治疗均可快速降低HbA1c达1.1%，显著优于格列美脲单药治疗或格列美脲联合罗格列酮治疗。格列美脲联合利拉鲁肽1.8mg/d治疗组患者体重降低，<10%的患者发生轻度低血糖。",
          "start_idx": 0,
          "end_idx": 218,
          "entities": [
            {
              "entity_id": "T272",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 10
            },
            {
              "entity_id": "T273",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 50
            },
            {
              "entity_id": "T274",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 62
            },
            {
              "entity_id": "T275",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 125
            },
            {
              "entity_id": "T276",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 131
            },
            {
              "entity_id": "T277",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 154,
              "end_idx": 158
            },
            {
              "entity_id": "T278",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167
            },
            {
              "entity_id": "T279",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 173
            },
            {
              "entity_id": "T280",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 176,
              "end_idx": 180
            },
            {
              "entity_id": "T281",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 186
            },
            {
              "entity_id": "T282",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 69
            },
            {
              "entity_id": "T283",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 139,
              "end_idx": 144
            },
            {
              "entity_id": "T284",
              "entity": "1.1%",
              "entity_type": "Test_Value",
              "start_idx": 145,
              "end_idx": 149
            },
            {
              "entity_id": "T285",
              "entity": "显著降低",
              "entity_type": "Test_Value",
              "start_idx": 71,
              "end_idx": 75
            },
            {
              "entity_id": "T286",
              "entity": "1.8mg/d",
              "entity_type": "Amount",
              "start_idx": 186,
              "end_idx": 193
            },
            {
              "entity_id": "T287",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 214,
              "end_idx": 217
            },
            {
              "entity_id": "T288",
              "entity": "体重降低",
              "entity_type": "ADE",
              "start_idx": 198,
              "end_idx": 202
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R102",
              "head_entity_id": "T288",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R103",
              "head_entity_id": "T287",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R104",
              "head_entity_id": "T286",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R105",
              "head_entity_id": "T288",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R106",
              "head_entity_id": "T287",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R107",
              "head_entity_id": "T286",
              "tail_entity_id": "T281"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "34",
      "paragraph": "3.9 磺脲类药物联合胰岛素的临床疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.9 磺脲类药物联合胰岛素的临床疗效如何? ",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T289",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T290",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 14
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "35",
      "paragraph": "一般情况下，不推荐磺脲类药物联合胰岛素治疗T2DM，但胰岛细胞尚有部分分泌功能的T2DM患者可考虑使用磺脲类药物联合基础胰岛素治疗。当单一或联合口服降糖药无法满意控制血糖时，口服降糖药物(包括磺脲类药物)联合基础胰岛素可以作为一种胰岛素起始的治疗方案。在亚洲多个国",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一般情况下，不推荐磺脲类药物联合胰岛素治疗T2DM，但胰岛细胞尚有部分分泌功能的T2DM患者可考虑使用磺脲类药物联合基础胰岛素治疗。当单一或联合口服降糖药无法满意控制血糖时，口服降糖药物(包括磺脲类药物)联合基础胰岛素可以作为一种胰岛素起始的治疗方案。",
          "start_idx": 0,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T291",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14
            },
            {
              "entity_id": "T292",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19
            },
            {
              "entity_id": "T293",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 56
            },
            {
              "entity_id": "T294",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 63
            },
            {
              "entity_id": "T295",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 101
            },
            {
              "entity_id": "T296",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 109
            },
            {
              "entity_id": "T297",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 87,
              "end_idx": 89
            },
            {
              "entity_id": "T298",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 72,
              "end_idx": 74
            },
            {
              "entity_id": "T299",
              "entity": "胰岛",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 117
            },
            {
              "entity_id": "T300",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 21,
              "end_idx": 23
            },
            {
              "entity_id": "T301",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T302",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 40,
              "end_idx": 42
            },
            {
              "entity_id": "T303",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 44
            },
            {
              "entity_id": "T304",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 83,
              "end_idx": 85
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R108",
              "head_entity_id": "T293",
              "tail_entity_id": "T303"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R109",
              "head_entity_id": "T294",
              "tail_entity_id": "T303"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R110",
              "head_entity_id": "T297",
              "tail_entity_id": "T295"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R111",
              "head_entity_id": "T297",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R112",
              "head_entity_id": "T300",
              "tail_entity_id": "T301"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R113",
              "head_entity_id": "T302",
              "tail_entity_id": "T303"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "在亚洲多个国",
          "start_idx": 126,
          "end_idx": 132,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "36",
      "paragraph": "家进行的一项443例T2DM患者参加的多中心、随机、对照研究显示，对于既往未接受胰岛素治疗的T2DM患者，格列美脲联合甘精胰岛素可进一步降低HbA1c达0.99%，HbA1c达标率为38.1%，空腹血糖降低幅度为5.89mmol/L，与格列美脲联合重组人胰岛素(NPH)组无差异，平均日间血糖降低幅度优于NPH组(-5.22mmol/L vs -4.44mmol/L)，总体低血糖发生682/220(次数/例数)，症状性低血糖为515/220(次数/例数)，严重低血糖为5/220(次数/例数)。接受磺脲类药物联合基础胰岛素治疗的患者应特别注意饮食和运动量，以及体重增加和低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "家进行的一项443例T2DM患者参加的多中心、随机、对照研究显示，对于既往未接受胰岛素治疗的T2DM患者，格列美脲联合甘精胰岛素可进一步降低HbA1c达0.99%，HbA1c达标率为38.1%，空腹血糖降低幅度为5.89mmol/L，与格列美脲联合重组人胰岛素(NPH)组无差异，平均日间血糖降低幅度优于NPH组(-5.22mmol/L vs -4.44mmol/L)，总体低血糖发生682/220(次数/例数)，症状性低血糖为515/220(次数/例数)，严重低血糖为5/220(次数/例数)。接受磺脲类药物联合基础胰岛素治疗的患者应特别注意饮食和运动量，以及体重增加和低血糖。",
          "start_idx": 0,
          "end_idx": 290,
          "entities": [
            {
              "entity_id": "T305",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 43
            },
            {
              "entity_id": "T306",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T307",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 64
            },
            {
              "entity_id": "T308",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 122
            },
            {
              "entity_id": "T309",
              "entity": "重组人胰岛素(NPH)",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 135
            },
            {
              "entity_id": "T310",
              "entity": "NPH",
              "entity_type": "Drug",
              "start_idx": 152,
              "end_idx": 155
            },
            {
              "entity_id": "T311",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 250,
              "end_idx": 255
            },
            {
              "entity_id": "T312",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 257,
              "end_idx": 262
            },
            {
              "entity_id": "T313",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 10,
              "end_idx": 12
            },
            {
              "entity_id": "T314",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T315",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 46,
              "end_idx": 48
            },
            {
              "entity_id": "T316",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 50
            },
            {
              "entity_id": "T317",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 70,
              "end_idx": 75
            },
            {
              "entity_id": "T318",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 87
            },
            {
              "entity_id": "T319",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 97,
              "end_idx": 101
            },
            {
              "entity_id": "T320",
              "entity": "平均日间血糖降低幅度",
              "entity_type": "Test_items",
              "start_idx": 140,
              "end_idx": 150
            },
            {
              "entity_id": "T321",
              "entity": "0.99%",
              "entity_type": "Test_Value",
              "start_idx": 76,
              "end_idx": 81
            },
            {
              "entity_id": "T322",
              "entity": "38.1%",
              "entity_type": "Test_Value",
              "start_idx": 91,
              "end_idx": 96
            },
            {
              "entity_id": "T323",
              "entity": "5.89mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 106,
              "end_idx": 116
            },
            {
              "entity_id": "T324",
              "entity": "-5.22mmol/L vs -4.44mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 157,
              "end_idx": 183
            },
            {
              "entity_id": "T325",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 187,
              "end_idx": 190
            },
            {
              "entity_id": "T326",
              "entity": "症状性低血糖",
              "entity_type": "ADE",
              "start_idx": 207,
              "end_idx": 213
            },
            {
              "entity_id": "T327",
              "entity": "严重低血糖",
              "entity_type": "ADE",
              "start_idx": 229,
              "end_idx": 234
            },
            {
              "entity_id": "T328",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 281,
              "end_idx": 285
            },
            {
              "entity_id": "T329",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 286,
              "end_idx": 289
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R114",
              "head_entity_id": "T306",
              "tail_entity_id": "T316"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R115",
              "head_entity_id": "T325",
              "tail_entity_id": "T306"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R116",
              "head_entity_id": "T326",
              "tail_entity_id": "T306"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R117",
              "head_entity_id": "T327",
              "tail_entity_id": "T306"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R118",
              "head_entity_id": "T307",
              "tail_entity_id": "T316"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R119",
              "head_entity_id": "T325",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R120",
              "head_entity_id": "T326",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R121",
              "head_entity_id": "T327",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R122",
              "head_entity_id": "T328",
              "tail_entity_id": "T311"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R123",
              "head_entity_id": "T329",
              "tail_entity_id": "T311"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R124",
              "head_entity_id": "T328",
              "tail_entity_id": "T312"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R125",
              "head_entity_id": "T329",
              "tail_entity_id": "T312"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R126",
              "head_entity_id": "T313",
              "tail_entity_id": "T314"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R127",
              "head_entity_id": "T315",
              "tail_entity_id": "T316"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "37",
      "paragraph": "4 特殊人群用药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4 特殊人群用药",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "38",
      "paragraph": "4.1 肝功能不全的T2DM患者是否可以使用磺脲类药物? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.1 肝功能不全的T2DM患者是否可以使用磺脲类药物? ",
          "start_idx": 0,
          "end_idx": 29,
          "entities": [
            {
              "entity_id": "T330",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T331",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 5
            },
            {
              "entity_id": "T332",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 10,
              "end_idx": 12
            },
            {
              "entity_id": "T333",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T334",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 27
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R128",
              "head_entity_id": "T331",
              "tail_entity_id": "T330"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "39",
      "paragraph": "目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(alanine transaminase，ALT)>3倍参考值上限可作为肝损害的敏感而特异的指标，若ALT>8~10倍参考值上限或者ALT>3倍参考值上限且血清总胆红素(total bilirubin，TBIL)>2倍参考值上限则是预测重度肝损害的特异指标，表明肝脏实质细胞受到损害，此时应禁用磺脲类药物。在临床使用中，伴有肝性脑病、腹水或凝血障碍的失代偿肝硬化患者应禁用该类药物以防发生低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(alanine transaminase，ALT)>3倍参考值上限可作为肝损害的敏感而特异的指标，若ALT>8~10倍参考值上限或者ALT>3倍参考值上限且血清总胆红素(total bilirubin，TBIL)>2倍参考值上限则是预测重度肝损害的特异指标，表明肝脏实质细胞受到损害，此时应禁用磺脲类药物。在临床使用中，伴有肝性脑病、腹水或凝血障碍的失代偿肝硬化患者应禁用该类药物以防发生低血糖。",
          "start_idx": 0,
          "end_idx": 234,
          "entities": [
            {
              "entity_id": "T335",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T336",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 14,
              "end_idx": 16
            },
            {
              "entity_id": "T337",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 21
            },
            {
              "entity_id": "T338",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 16,
              "end_idx": 17
            },
            {
              "entity_id": "T339",
              "entity": "丙氨酸氨基转移酶(alanine transaminase，ALT)",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 61
            },
            {
              "entity_id": "T340",
              "entity": ">3",
              "entity_type": "Test_Value",
              "start_idx": 61,
              "end_idx": 63
            },
            {
              "entity_id": "T341",
              "entity": "肝损害",
              "entity_type": "ADE",
              "start_idx": 72,
              "end_idx": 75
            },
            {
              "entity_id": "T342",
              "entity": "ALT",
              "entity_type": "Test_items",
              "start_idx": 86,
              "end_idx": 89
            },
            {
              "entity_id": "T343",
              "entity": ">8~10",
              "entity_type": "Test_Value",
              "start_idx": 89,
              "end_idx": 94
            },
            {
              "entity_id": "T344",
              "entity": "ALT",
              "entity_type": "Test_items",
              "start_idx": 102,
              "end_idx": 105
            },
            {
              "entity_id": "T345",
              "entity": ">3",
              "entity_type": "Test_Value",
              "start_idx": 105,
              "end_idx": 107
            },
            {
              "entity_id": "T346",
              "entity": "血清总胆红素(total bilirubin，TBIL)",
              "entity_type": "Test_items",
              "start_idx": 114,
              "end_idx": 142
            },
            {
              "entity_id": "T347",
              "entity": ">2",
              "entity_type": "Test_Value",
              "start_idx": 142,
              "end_idx": 144
            },
            {
              "entity_id": "T348",
              "entity": "重度肝损害",
              "entity_type": "ADE",
              "start_idx": 154,
              "end_idx": 159
            },
            {
              "entity_id": "T349",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 183,
              "end_idx": 188
            },
            {
              "entity_id": "T350",
              "entity": "肝性脑病",
              "entity_type": "Disease",
              "start_idx": 198,
              "end_idx": 202
            },
            {
              "entity_id": "T351",
              "entity": "腹水",
              "entity_type": "Disease",
              "start_idx": 203,
              "end_idx": 205
            },
            {
              "entity_id": "T352",
              "entity": "失代偿肝硬化",
              "entity_type": "Disease",
              "start_idx": 211,
              "end_idx": 217
            },
            {
              "entity_id": "T353",
              "entity": "凝血障碍",
              "entity_type": "Disease",
              "start_idx": 206,
              "end_idx": 210
            },
            {
              "entity_id": "T354",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 230,
              "end_idx": 233
            },
            {
              "entity_id": "T355",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 198,
              "end_idx": 199
            },
            {
              "entity_id": "T356",
              "entity": "脑",
              "entity_type": "Anatomy",
              "start_idx": 200,
              "end_idx": 201
            },
            {
              "entity_id": "T357",
              "entity": "腹",
              "entity_type": "Anatomy",
              "start_idx": 203,
              "end_idx": 204
            },
            {
              "entity_id": "T358",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 214,
              "end_idx": 215
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R129",
              "head_entity_id": "T341",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R130",
              "head_entity_id": "T354",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R131",
              "head_entity_id": "T348",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R132",
              "head_entity_id": "T338",
              "tail_entity_id": "T337"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R133",
              "head_entity_id": "T355",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R134",
              "head_entity_id": "T356",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R135",
              "head_entity_id": "T357",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R136",
              "head_entity_id": "T358",
              "tail_entity_id": "T352"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "40",
      "paragraph": "4.2 肾功能不全的T2DM患者是否可以使用磺脲类药物? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.2 肾功能不全的T2DM患者是否可以使用磺脲类药物? ",
          "start_idx": 0,
          "end_idx": 29,
          "entities": [
            {
              "entity_id": "T359",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T360",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 5
            },
            {
              "entity_id": "T361",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 10,
              "end_idx": 12
            },
            {
              "entity_id": "T362",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T363",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 27
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R137",
              "head_entity_id": "T360",
              "tail_entity_id": "T359"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R138",
              "head_entity_id": "T361",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R139",
              "head_entity_id": "T363",
              "tail_entity_id": "T362"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "41",
      "paragraph": "格列本脲本身及其代谢产物均具有降糖活性，肾功能不全的T2DM患者使用格列本脲容易发生严重的低血糖事件；格列美脲的代谢产物在GFR降低的患者中没有额外蓄积风险；其他常用的磺脲类药物如格列喹酮、格列齐特及格列吡嗪，代谢产物均为非活性物质，尤其是格列喹酮，其代谢产物只有5%经肾脏排泄，受肾功能的影响很小，其可用于轻、中度肾功能不全的糖尿病患者。ADVANCE研究发现，格列齐特缓释片具有肾脏保护作用，可降低患者蛋白尿和肾脏事件风险。磺脲类药物在T2DM合并肾功能不全患者中的使用推荐见表3。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列本脲本身及其代谢产物均具有降糖活性，肾功能不全的T2DM患者使用格列本脲容易发生严重的低血糖事件；格列美脲的代谢产物在GFR降低的患者中没有额外蓄积风险；其他常用的磺脲类药物如格列喹酮、格列齐特及格列吡嗪，代谢产物均为非活性物质，尤其是格列喹酮，其代谢产物只有5%经肾脏排泄，受肾功能的影响很小，其可用于轻、中度肾功能不全的糖尿病患者。ADVANCE研究发现，格列齐特缓释片具有肾脏保护作用，可降低患者蛋白尿和肾脏事件风险。",
          "start_idx": 0,
          "end_idx": 214,
          "entities": [
            {
              "entity_id": "T364",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T365",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38
            },
            {
              "entity_id": "T366",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55
            },
            {
              "entity_id": "T367",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 89
            },
            {
              "entity_id": "T368",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 94
            },
            {
              "entity_id": "T369",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T370",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 104
            },
            {
              "entity_id": "T371",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 124
            },
            {
              "entity_id": "T372",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 189
            },
            {
              "entity_id": "T374",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25
            },
            {
              "entity_id": "T375",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 20,
              "end_idx": 21
            },
            {
              "entity_id": "T376",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T377",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 30
            },
            {
              "entity_id": "T378",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 45,
              "end_idx": 48
            },
            {
              "entity_id": "T379",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 163
            },
            {
              "entity_id": "T380",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 158,
              "end_idx": 159
            },
            {
              "entity_id": "T381",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 164,
              "end_idx": 167
            },
            {
              "entity_id": "T382",
              "entity": "蛋白尿",
              "entity_type": "ADE",
              "start_idx": 203,
              "end_idx": 206
            },
            {
              "entity_id": "T383",
              "entity": "肾脏事件",
              "entity_type": "ADE",
              "start_idx": 207,
              "end_idx": 211
            },
            {
              "entity_id": "T388",
              "entity": "轻、中度",
              "entity_type": "Level",
              "start_idx": 154,
              "end_idx": 158
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R140",
              "head_entity_id": "T365",
              "tail_entity_id": "T377"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R141",
              "head_entity_id": "T371",
              "tail_entity_id": "T381"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R142",
              "head_entity_id": "T382",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R143",
              "head_entity_id": "T383",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R145",
              "head_entity_id": "T375",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R146",
              "head_entity_id": "T376",
              "tail_entity_id": "T377"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "磺脲类药物在T2DM合并肾功能不全患者中的使用推荐见表3。",
          "start_idx": 214,
          "end_idx": 243,
          "entities": [
            {
              "entity_id": "T373",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T384",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8
            },
            {
              "entity_id": "T385",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T386",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17
            },
            {
              "entity_id": "T387",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R144",
              "head_entity_id": "T373",
              "tail_entity_id": "T385"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R147",
              "head_entity_id": "T384",
              "tail_entity_id": "T385"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R148",
              "head_entity_id": "T387",
              "tail_entity_id": "T386"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "42",
      "paragraph": "4.3 老年患者使用磺脲类药物有哪些注意事项? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.3 老年患者使用磺脲类药物有哪些注意事项? ",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T389",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "43",
      "paragraph": "针对老年糖尿病患者，实施个体化药物治疗方案控制血糖并避免或最小化药物相关的不良反应是必要的。老年糖尿病患者对低血糖耐受性差，易出现无症状性低血糖和严重低血糖，需要特别关注。因此，在选择降糖药物时，老年患者应着重考虑药物的低血糖风险。若患者既往有严重低血糖史、预期生存期较短、或合并其他严重疾病，如果需要联合磺脲类药物治疗，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖的发生风险降至最小。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "针对老年糖尿病患者，实施个体化药物治疗方案控制血糖并避免或最小化药物相关的不良反应是必要的。老年糖尿病患者对低血糖耐受性差，易出现无症状性低血糖和严重低血糖，需要特别关注。因此，在选择降糖药物时，老年患者应着重考虑药物的低血糖风险。若患者既往有严重低血糖史、预期生存期较短、或合并其他严重疾病，如果需要联合磺脲类药物治疗，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖的发生风险降至最小。",
          "start_idx": 0,
          "end_idx": 260,
          "entities": [
            {
              "entity_id": "T390",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7
            },
            {
              "entity_id": "T391",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25
            },
            {
              "entity_id": "T392",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51
            },
            {
              "entity_id": "T393",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57
            },
            {
              "entity_id": "T394",
              "entity": "无症状性低血糖",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 72
            },
            {
              "entity_id": "T395",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 110,
              "end_idx": 113
            },
            {
              "entity_id": "T396",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 124,
              "end_idx": 127
            },
            {
              "entity_id": "T397",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 122,
              "end_idx": 124
            },
            {
              "entity_id": "T398",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 153,
              "end_idx": 158
            },
            {
              "entity_id": "T399",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 179,
              "end_idx": 182
            },
            {
              "entity_id": "T400",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 186,
              "end_idx": 191
            },
            {
              "entity_id": "T401",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 196,
              "end_idx": 200
            },
            {
              "entity_id": "T402",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 207,
              "end_idx": 212
            },
            {
              "entity_id": "T403",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 227,
              "end_idx": 229
            },
            {
              "entity_id": "T404",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 234,
              "end_idx": 236
            },
            {
              "entity_id": "T405",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 247,
              "end_idx": 250
            },
            {
              "entity_id": "T406",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 78
            },
            {
              "entity_id": "T407",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 73,
              "end_idx": 75
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R149",
              "head_entity_id": "T391",
              "tail_entity_id": "T390"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R150",
              "head_entity_id": "T399",
              "tail_entity_id": "T400"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R151",
              "head_entity_id": "T399",
              "tail_entity_id": "T401"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R152",
              "head_entity_id": "T405",
              "tail_entity_id": "T402"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "44",
      "paragraph": "4.4 磺脲类药物可否用于T2DM之外的糖尿病患者? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.4 磺脲类药物可否用于T2DM之外的糖尿病患者? ",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T408",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T409",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 15
            },
            {
              "entity_id": "T410",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 17
            },
            {
              "entity_id": "T411",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R153",
              "head_entity_id": "T408",
              "tail_entity_id": "T411"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R154",
              "head_entity_id": "T409",
              "tail_entity_id": "T410"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "45",
      "paragraph": "目前为止，所有磺脲类药物均尚未被中国食品药品监督管理局(China Food and Drug Administration，CFDA)批准用于治疗妊娠期糖尿病、儿童和青少年T2DM以及1型糖尿病患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前为止，所有磺脲类药物均尚未被中国食品药品监督管理局(China Food and Drug Administration，CFDA)批准用于治疗妊娠期糖尿病、儿童和青少年T2DM以及1型糖尿病患者。",
          "start_idx": 0,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T412",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 12
            },
            {
              "entity_id": "T413",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 87,
              "end_idx": 89
            },
            {
              "entity_id": "T414",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 87,
              "end_idx": 91
            },
            {
              "entity_id": "T415",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 93,
              "end_idx": 95
            },
            {
              "entity_id": "T416",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 93,
              "end_idx": 98
            },
            {
              "entity_id": "T417",
              "entity": "妊娠期",
              "entity_type": "Class",
              "start_idx": 74,
              "end_idx": 77
            },
            {
              "entity_id": "T418",
              "entity": "妊娠期糖尿病",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 80
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R155",
              "head_entity_id": "T413",
              "tail_entity_id": "T414"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R156",
              "head_entity_id": "T415",
              "tail_entity_id": "T416"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R157",
              "head_entity_id": "T417",
              "tail_entity_id": "T418"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "46",
      "paragraph": "5 安全性",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5 安全性",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "47",
      "paragraph": "5.1 磺脲类药物有哪些常见不良反应? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.1 磺脲类药物有哪些常见不良反应? ",
          "start_idx": 0,
          "end_idx": 20,
          "entities": [
            {
              "entity_id": "T419",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "48",
      "paragraph": "磺脲类药物治疗常见的不良反应有以下几种：①低血糖：临床上起始磺脲类药物剂量过大，或在肝、肾功能不全患者中的不恰当使用可导致低血糖；单药治疗或与其他降糖药物联合治疗均可能出现低血糖。②体重增加。③磺脲类药物与磺胺类药物可发生交叉过敏反应，有磺胺类药物过敏史者应禁用磺脲类药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物治疗常见的不良反应有以下几种：①低血糖：临床上起始磺脲类药物剂量过大，或在肝、肾功能不全患者中的不恰当使用可导致低血糖；单药治疗或与其他降糖药物联合治疗均可能出现低血糖。②体重增加。③磺脲类药物与磺胺类药物可发生交叉过敏反应，有磺胺类药物过敏史者应禁用磺脲类药物。",
          "start_idx": 0,
          "end_idx": 137,
          "entities": [
            {
              "entity_id": "T420",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T421",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 21,
              "end_idx": 24
            },
            {
              "entity_id": "T422",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 61,
              "end_idx": 64
            },
            {
              "entity_id": "T423",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 86,
              "end_idx": 89
            },
            {
              "entity_id": "T424",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 91,
              "end_idx": 95
            },
            {
              "entity_id": "T425",
              "entity": "交叉过敏反应",
              "entity_type": "ADE",
              "start_idx": 111,
              "end_idx": 117
            },
            {
              "entity_id": "T426",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 35
            },
            {
              "entity_id": "T427",
              "entity": "肝、肾功能不全",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 49
            },
            {
              "entity_id": "T428",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 42,
              "end_idx": 43
            },
            {
              "entity_id": "T429",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 44,
              "end_idx": 45
            },
            {
              "entity_id": "T430",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 102
            },
            {
              "entity_id": "T431",
              "entity": "磺胺类药物",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 108
            },
            {
              "entity_id": "T432",
              "entity": "磺胺类药物",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 124
            },
            {
              "entity_id": "T433",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 136
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R158",
              "head_entity_id": "T421",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R159",
              "head_entity_id": "T422",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R160",
              "head_entity_id": "T423",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R161",
              "head_entity_id": "T424",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R162",
              "head_entity_id": "T425",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R163",
              "head_entity_id": "T428",
              "tail_entity_id": "T427"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R164",
              "head_entity_id": "T429",
              "tail_entity_id": "T427"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "49",
      "paragraph": "5.2 如何预防磺脲类药物治疗导致的低血糖? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.2 如何预防磺脲类药物治疗导致的低血糖? ",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T434",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T435",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 18,
              "end_idx": 21
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R165",
              "head_entity_id": "T435",
              "tail_entity_id": "T434"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "50",
      "paragraph": "荟萃分析结果显示，正确使用磺脲类药物单药及联合治疗的患者，轻、中度低血糖发生率为1.92例/(患者·年)，重度低血糖发生率为0.01例/(患者·年)。不同磺脲类药物的作用机制及剂型存在差异，其低血糖发生率也不同，其中格列本脲导致低血糖的发生风险最高。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "荟萃分析结果显示，正确使用磺脲类药物单药及联合治疗的患者，轻、中度低血糖发生率为1.92例/(患者·年)，重度低血糖发生率为0.01例/(患者·年)。不同磺脲类药物的作用机制及剂型存在差异，其低血糖发生率也不同，其中格列本脲导致低血糖的发生风险最高。",
          "start_idx": 0,
          "end_idx": 125,
          "entities": [
            {
              "entity_id": "T436",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 18
            },
            {
              "entity_id": "T437",
              "entity": "轻、中度低血糖",
              "entity_type": "ADE",
              "start_idx": 29,
              "end_idx": 36
            },
            {
              "entity_id": "T438",
              "entity": "重度低血糖",
              "entity_type": "ADE",
              "start_idx": 53,
              "end_idx": 58
            },
            {
              "entity_id": "T439",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 82
            },
            {
              "entity_id": "T440",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 97,
              "end_idx": 99
            },
            {
              "entity_id": "T441",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 112
            },
            {
              "entity_id": "T442",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 114,
              "end_idx": 117
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R166",
              "head_entity_id": "T437",
              "tail_entity_id": "T436"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R167",
              "head_entity_id": "T438",
              "tail_entity_id": "T436"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R168",
              "head_entity_id": "T442",
              "tail_entity_id": "T441"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "52",
      "paragraph": "5.3 如何看待磺脲类药物增加体重的问题? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.3 如何看待磺脲类药物增加体重的问题? ",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T443",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T444",
              "entity": "增加体重",
              "entity_type": "ADE",
              "start_idx": 13,
              "end_idx": 17
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R169",
              "head_entity_id": "T444",
              "tail_entity_id": "T443"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "54",
      "paragraph": "5.4 磺脲类药物的心血管安全性如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.4 磺脲类药物的心血管安全性如何? ",
          "start_idx": 0,
          "end_idx": 20,
          "entities": [
            {
              "entity_id": "T445",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "55",
      "paragraph": "不同磺脲类药物的心血管安全性可能存在差异。包括UKPDS和ADVANCE等多项大型临床研究结果均证实了磺脲类药物在降糖治疗中的心血管安全性。荟萃分析结果发现，与格列本脲相比，格列齐特和格列美脲可降低T2DM患者的全因死亡风险，而格列吡嗪、甲苯磺丁脲及氯磺丙脲则无此差异。一项为期5年的大样本观察性研究发现，使用格列齐特治疗的患者总病死率和心血管事件死亡率均低于格列本脲，这可能与格列齐特能选择性激活胰岛β细胞的磺脲类受体1(sulfonylurea receptor，SUR1)，而对心肌细胞上的SUR2A和血管平滑肌细胞上的SUR2B无活化作用有关。另外，体外试验证实格列喹酮对胰岛β细胞同样具有高选择性，推测其同样具有较好的心血管安全性。总之，在评价不同磺脲类药物的心血管安全性时，需要具体问题具体分析。磺脲类药物的心血管安全性问题仍需设计优良的前瞻性随机对照研究加以解决。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "不同磺脲类药物的心血管安全性可能存在差异。",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T446",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "包括UKPDS和ADVANCE等多项大型临床研究结果均证实了磺脲类药物在降糖治疗中的心血管安全性。荟萃分析结果发现，与格列本脲相比，格列齐特和格列美脲可降低T2DM患者的全因死亡风险，而格列吡嗪、甲苯磺丁脲及氯磺丙脲则无此差异。一项为期5年的大样本观察性研究发现，使用格列齐特治疗的患者总病死率和心血管事件死亡率均低于格列本脲，这可能与格列齐特能选择性激活胰岛β细胞的磺脲类受体1(sulfonylurea receptor，SUR1)，而对心肌细胞上的SUR2A和血管平滑肌细胞上的SUR2B无活化作用有关。",
          "start_idx": 21,
          "end_idx": 276,
          "entities": [
            {
              "entity_id": "T447",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 35
            },
            {
              "entity_id": "T448",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63
            },
            {
              "entity_id": "T449",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 70
            },
            {
              "entity_id": "T450",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 71,
              "end_idx": 75
            },
            {
              "entity_id": "T451",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 97
            },
            {
              "entity_id": "T452",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 98,
              "end_idx": 103
            },
            {
              "entity_id": "T453",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108
            },
            {
              "entity_id": "T454",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138
            },
            {
              "entity_id": "T455",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 159,
              "end_idx": 163
            },
            {
              "entity_id": "T456",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 168,
              "end_idx": 172
            },
            {
              "entity_id": "T460",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 78,
              "end_idx": 80
            },
            {
              "entity_id": "T461",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 82
            },
            {
              "entity_id": "T462",
              "entity": "心血管事件",
              "entity_type": "ADE",
              "start_idx": 148,
              "end_idx": 153
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R170",
              "head_entity_id": "T449",
              "tail_entity_id": "T461"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R171",
              "head_entity_id": "T450",
              "tail_entity_id": "T461"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R172",
              "head_entity_id": "T462",
              "tail_entity_id": "T454"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R173",
              "head_entity_id": "T462",
              "tail_entity_id": "T455"
            }
          ]
        },
        {
          "sentence_id": "2",
          "sentence": "另外，体外试验证实格列喹酮对胰岛β细胞同样具有高选择性，推测其同样具有较好的心血管安全性。",
          "start_idx": 276,
          "end_idx": 321,
          "entities": [
            {
              "entity_id": "T457",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "总之，在评价不同磺脲类药物的心血管安全性时，需要具体问题具体分析。",
          "start_idx": 321,
          "end_idx": 354,
          "entities": [
            {
              "entity_id": "T458",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "4",
          "sentence": "磺脲类药物的心血管安全性问题仍需设计优良的前瞻性随机对照研究加以解决。",
          "start_idx": 354,
          "end_idx": 389,
          "entities": [
            {
              "entity_id": "T459",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "56",
      "paragraph": "5.5 磺脲类药物会加速β细胞功能衰退吗? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.5 磺脲类药物会加速β细胞功能衰退吗? ",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T463",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T464",
              "entity": "β细胞功能衰退",
              "entity_type": "ADE",
              "start_idx": 12,
              "end_idx": 19
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R174",
              "head_entity_id": "T464",
              "tail_entity_id": "T463"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "57",
      "paragraph": "β细胞功能凋亡的机制尚未完全明确。持续20年的UKPDS研究结果表明，磺脲类药物并未加速β细胞功能衰竭。ADOPT研究终点时，格列本脲组β细胞胰岛素分泌功能和罗格列酮组相似。中国一项多中心研究结果显示，格列齐特缓释片强化治疗3个月可使约60%的患者血糖达标，停药2日后复查口服葡萄糖耐量试验，恢复为正常糖耐量或糖耐量受损者占22.83%，这说明磺脲类药物强化治疗显著改善了早相胰岛素分泌功能。因此，目前尚无直接证据表明磺脲类药物治疗与β细胞功能衰退有关。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "β细胞功能凋亡的机制尚未完全明确。",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "持续20年的UKPDS研究结果表明，磺脲类药物并未加速β细胞功能衰竭。ADOPT研究终点时，格列本脲组β细胞胰岛素分泌功能和罗格列酮组相似。中国一项多中心研究结果显示，格列齐特缓释片强化治疗3个月可使约60%的患者血糖达标，停药2日后复查口服葡萄糖耐量试验，恢复为正常糖耐量或糖耐量受损者占22.83%，这说明磺脲类药物强化治疗显著改善了早相胰岛素分泌功能。",
          "start_idx": 17,
          "end_idx": 196,
          "entities": [
            {
              "entity_id": "T465",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 23
            },
            {
              "entity_id": "T466",
              "entity": "β细胞功能衰竭",
              "entity_type": "Symptom",
              "start_idx": 27,
              "end_idx": 34
            },
            {
              "entity_id": "T467",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 50
            },
            {
              "entity_id": "T468",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 66
            },
            {
              "entity_id": "T469",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 91
            },
            {
              "entity_id": "T470",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 160
            },
            {
              "entity_id": "T472",
              "entity": "3个月",
              "entity_type": "Duration",
              "start_idx": 95,
              "end_idx": 98
            },
            {
              "entity_id": "T473",
              "entity": "口服葡萄糖耐量试验",
              "entity_type": "Test",
              "start_idx": 119,
              "end_idx": 128
            },
            {
              "entity_id": "T475",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 107,
              "end_idx": 109
            }
          ],
          "relations": [
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R175",
              "head_entity_id": "T472",
              "tail_entity_id": "T469"
            }
          ]
        },
        {
          "sentence_id": "2",
          "sentence": "因此，目前尚无直接证据表明磺脲类药物治疗与β细胞功能衰退有关。",
          "start_idx": 196,
          "end_idx": 227,
          "entities": [
            {
              "entity_id": "T471",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 18
            },
            {
              "entity_id": "T474",
              "entity": "β细胞功能衰退",
              "entity_type": "Symptom",
              "start_idx": 21,
              "end_idx": 28
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "58",
      "paragraph": "逆向的传导，使患者心肌细胞的自发性兴奋度下降，从而消除折返激动，放慢传导的速度，药效比较持久迅速，但与胺碘酮的治疗效果比较要低一些。胺碘酮作为III类抗心律失常药物，能较为迅速地阻断钾离子的传导通道，从而使心肌兴奋度下降，降低窦房结的自律性，消除折返激动，具有I类和IV类抗心律失常药物的特性，有显著的治疗效果。在本次研究中，治疗组治疗的有效率高于对照组20.93%，并且治疗组血液流变学指标改善较对照组明显，改善后的指标值优于对照组(P<0.05)；治疗组患者服用胺碘酮片后hs-CRP水平明显下降，下降水平同样优于对照组(P<0.05)；治疗组不良反应发生与对照组比较没有较大的差异性(P>0.05)。该研究说明，虽然两种药物的不良反应没有较大差异，但胺碘酮治疗的效果明显优于心律平片，研究结果与学者刘荣魁、许有凡的研究结果基本一致。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "逆向的传导，使患者心肌细胞的自发性兴奋度下降，从而消除折返激动，放慢传导的速度，药效比较持久迅速，但与胺碘酮的治疗效果比较要低一些。",
          "start_idx": 0,
          "end_idx": 66,
          "entities": [
            {
              "entity_id": "T476",
              "entity": "胺碘酮",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 54
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "胺碘酮作为III类抗心律失常药物，能较为迅速地阻断钾离子的传导通道，从而使心肌兴奋度下降，降低窦房结的自律性，消除折返激动，具有I类和IV类抗心律失常药物的特性，有显著的治疗效果。",
          "start_idx": 66,
          "end_idx": 156,
          "entities": [
            {
              "entity_id": "T477",
              "entity": "胺碘酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "在本次研究中，治疗组治疗的有效率高于对照组20.93%，并且治疗组血液流变学指标改善较对照组明显，改善后的指标值优于对照组(P<0.05)；治疗组患者服用胺碘酮片后hs-CRP水平明显下降，下降水平同样优于对照组(P<0.05)；治疗组不良反应发生与对照组比较没有较大的差异性(P>0.05)。",
          "start_idx": 156,
          "end_idx": 303,
          "entities": [
            {
              "entity_id": "T478",
              "entity": "胺碘酮片",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 81
            },
            {
              "entity_id": "T481",
              "entity": "hs-CRP",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 88
            },
            {
              "entity_id": "T482",
              "entity": "明显下降",
              "entity_type": "Test_Value",
              "start_idx": 90,
              "end_idx": 94
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "该研究说明，虽然两种药物的不良反应没有较大差异，但胺碘酮治疗的效果明显优于心律平片，研究结果与学者刘荣魁、许有凡的研究结果基本一致。",
          "start_idx": 303,
          "end_idx": 369,
          "entities": [
            {
              "entity_id": "T479",
              "entity": "胺碘酮",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 28
            },
            {
              "entity_id": "T480",
              "entity": "心律平片",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "59",
      "paragraph": "总之，采用胺碘酮治疗的效果更为显著，明显地改善了患者的血液流变学指标，使hs-CRP水平明显降低，值得临床推广应用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "总之，采用胺碘酮治疗的效果更为显著，明显地改善了患者的血液流变学指标，使hs-CRP水平明显降低，值得临床推广应用。",
          "start_idx": 0,
          "end_idx": 58,
          "entities": [
            {
              "entity_id": "T483",
              "entity": "胺碘酮",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8
            },
            {
              "entity_id": "T484",
              "entity": "hs-CRP",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 42
            },
            {
              "entity_id": "T485",
              "entity": "明显降低",
              "entity_type": "Test_Value",
              "start_idx": 44,
              "end_idx": 48
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "53",
      "paragraph": "目前普遍认为长期使用磺脲类药物可致患者体重明显增加，但不同磺脲类药物对体重的影响存在差异。剂型改良后的磺脲类药物及格列美脲对体重影响较小。随机对照研究结果显示，2型糖尿病患者使用格列吡嗪单药治疗1年体重增加2.6kg。GUIDE研究中随机分为格列齐特缓释片组和格列美脲组治疗27周，体重增加分别为0.5kg和0.6kg。荟萃分析结果显示，磺脲类药物单药治疗平均约增加体重2kg，但磺脲类药物与二甲双胍、SGLT-2抑制剂、GLP-1受体激动剂等药物联合时，这一不良反应可能会被完全或部分抵消。ZODIAC-39队列研究显示，不同磺脲类药物联合二甲双胍治疗5年，格列本脲组体重增加3.3kg，格列齐特组体重增加3.9kg，格列美脲组体重增加0.1kg。LEAD-1研究显示，之前使用格列美脲单药治疗的T2DM患者换为格列美脲联合利拉鲁肽1.2mg/d或1.8mg/d治疗后，体重变化分别为+0.3kg和-0.2kg。格列美脲单药治疗血糖控制不佳的患者，加用达格列净后不仅可以进一步改善血糖，还可改善体重。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前普遍认为长期使用磺脲类药物可致患者体重明显增加，但不同磺脲类药物对体重的影响存在差异。剂型改良后的磺脲类药物及格列美脲对体重影响较小。随机对照研究结果显示，2型糖尿病患者使用格列吡嗪单药治疗1年体重增加2.6kg。GUIDE研究中随机分为格列齐特缓释片组和格列美脲组治疗27周，体重增加分别为0.5kg和0.6kg。荟萃分析结果显示，磺脲类药物单药治疗平均约增加体重2kg，但磺脲类药物与二甲双胍、SGLT-2抑制剂、GLP-1受体激动剂等药物联合时，这一不良反应可能会被完全或部分抵消。ZODIAC-39队列研究显示，不同磺脲类药物联合二甲双胍治疗5年，格列本脲组体重增加3.3kg，格列齐特组体重增加3.9kg，格列美脲组体重增加0.1kg。LEAD-1研究显示，之前使用格列美脲单药治疗的T2DM患者换为格列美脲联合利拉鲁肽1.2mg/d或1.8mg/d治疗后，体重变化分别为+0.3kg和-0.2kg。",
          "start_idx": 0,
          "end_idx": 407,
          "entities": [
            {
              "entity_id": "T486",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15
            },
            {
              "entity_id": "T487",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T488",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 56
            },
            {
              "entity_id": "T489",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61
            },
            {
              "entity_id": "T490",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93
            },
            {
              "entity_id": "T491",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 128
            },
            {
              "entity_id": "T492",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134
            },
            {
              "entity_id": "T493",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 174
            },
            {
              "entity_id": "T494",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 195
            },
            {
              "entity_id": "T495",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 196,
              "end_idx": 200
            },
            {
              "entity_id": "T496",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 201,
              "end_idx": 210
            },
            {
              "entity_id": "T497",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 211,
              "end_idx": 221
            },
            {
              "entity_id": "T498",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 264,
              "end_idx": 269
            },
            {
              "entity_id": "T499",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 271,
              "end_idx": 275
            },
            {
              "entity_id": "T500",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 280,
              "end_idx": 284
            },
            {
              "entity_id": "T501",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 295,
              "end_idx": 299
            },
            {
              "entity_id": "T502",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 310,
              "end_idx": 314
            },
            {
              "entity_id": "T503",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 340,
              "end_idx": 344
            },
            {
              "entity_id": "T504",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 357,
              "end_idx": 361
            },
            {
              "entity_id": "T505",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 363,
              "end_idx": 367
            },
            {
              "entity_id": "T508",
              "entity": "体重明显增加",
              "entity_type": "ADE",
              "start_idx": 19,
              "end_idx": 25
            },
            {
              "entity_id": "T509",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 80,
              "end_idx": 82
            },
            {
              "entity_id": "T510",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 80,
              "end_idx": 85
            },
            {
              "entity_id": "T511",
              "entity": "1年",
              "entity_type": "Duration",
              "start_idx": 97,
              "end_idx": 99
            },
            {
              "entity_id": "T512",
              "entity": "27周",
              "entity_type": "Duration",
              "start_idx": 137,
              "end_idx": 140
            },
            {
              "entity_id": "T513",
              "entity": "5年",
              "entity_type": "Duration",
              "start_idx": 277,
              "end_idx": 279
            },
            {
              "entity_id": "T514",
              "entity": "1.2mg/d",
              "entity_type": "Amount",
              "start_idx": 367,
              "end_idx": 374
            },
            {
              "entity_id": "T515",
              "entity": "1.8mg/d",
              "entity_type": "Amount",
              "start_idx": 375,
              "end_idx": 382
            },
            {
              "entity_id": "T516",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 349,
              "end_idx": 351
            },
            {
              "entity_id": "T517",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 349,
              "end_idx": 353
            },
            {
              "entity_id": "T520",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 99,
              "end_idx": 103
            },
            {
              "entity_id": "T521",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 141,
              "end_idx": 145
            },
            {
              "entity_id": "T522",
              "entity": "增加体重",
              "entity_type": "ADE",
              "start_idx": 181,
              "end_idx": 185
            },
            {
              "entity_id": "T523",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 285,
              "end_idx": 289
            },
            {
              "entity_id": "T524",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 300,
              "end_idx": 304
            },
            {
              "entity_id": "T525",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 315,
              "end_idx": 319
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R176",
              "head_entity_id": "T508",
              "tail_entity_id": "T486"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R177",
              "head_entity_id": "T520",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R178",
              "head_entity_id": "T511",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R179",
              "head_entity_id": "T490",
              "tail_entity_id": "T510"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R180",
              "head_entity_id": "T521",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R181",
              "head_entity_id": "T512",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R182",
              "head_entity_id": "T521",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R183",
              "head_entity_id": "T512",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R184",
              "head_entity_id": "T522",
              "tail_entity_id": "T493"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R185",
              "head_entity_id": "T513",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R186",
              "head_entity_id": "T513",
              "tail_entity_id": "T499"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R187",
              "head_entity_id": "T523",
              "tail_entity_id": "T500"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R188",
              "head_entity_id": "T524",
              "tail_entity_id": "T501"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R189",
              "head_entity_id": "T525",
              "tail_entity_id": "T502"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R190",
              "head_entity_id": "T504",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R191",
              "head_entity_id": "T514",
              "tail_entity_id": "T505"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R192",
              "head_entity_id": "T515",
              "tail_entity_id": "T505"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R193",
              "head_entity_id": "T505",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R194",
              "head_entity_id": "T509",
              "tail_entity_id": "T510"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R195",
              "head_entity_id": "T516",
              "tail_entity_id": "T517"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "格列美脲单药治疗血糖控制不佳的患者，加用达格列净后不仅可以进一步改善血糖，还可改善体重。",
          "start_idx": 407,
          "end_idx": 451,
          "entities": [
            {
              "entity_id": "T506",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T507",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 24
            },
            {
              "entity_id": "T518",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 10
            },
            {
              "entity_id": "T519",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 34,
              "end_idx": 36
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "51",
      "paragraph": "增加磺脲类药物发生低血糖事件的主要因素有：高龄，饮酒，合并肝、肾疾病，药物过量，药物相互作用等。糖尿病患者在使用磺脲类药物时，预防低血糖的措施包括：①年长、体弱的患者建议选用低血糖风险相对低的格列齐特缓释片、格列美脲，或者其他短效制剂；2应从小剂量开始服用，并根据血糖监测结果缓慢加量至最佳剂量；③饮食方面应定食定量，避免餐前剧烈运动。如果出现腹泻、呕吐等症状，应减少药物剂量；④每天的运动量应保持相对稳定。运动量过大也可引起低血糖，在外出旅游、登山时，应适量增加饮食。对于绝大多数可被患者察觉的、有症状的低血糖事件，可通过补充含糖食物或口服/静脉推注20g葡萄糖予以纠正，若15~20min后症状仍不能缓解或血浆葡萄糖水平仍很低可以重复给予葡萄糖。对于发生严重低血糖事件的患者，尤其格列本脲所致者，需在静脉推注葡萄糖后给予较长时间(24~72h)的葡萄糖静脉滴注以防止低血糖的再次发生，并至少观察3d，密切监测血糖水平。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "增加磺脲类药物发生低血糖事件的主要因素有：高龄，饮酒，合并肝、肾疾病，药物过量，药物相互作用等。糖尿病患者在使用磺脲类药物时，预防低血糖的措施包括：①年长、体弱的患者建议选用低血糖风险相对低的格列齐特缓释片、格列美脲，或者其他短效制剂；2应从小剂量开始服用，并根据血糖监测结果缓慢加量至最佳剂量；③饮食方面应定食定量，避免餐前剧烈运动。如果出现腹泻、呕吐等症状，应减少药物剂量；④每天的运动量应保持相对稳定。运动量过大也可引起低血糖，在外出旅游、登山时，应适量增加饮食。对于绝大多数可被患者察觉的、有症状的低血糖事件，可通过补充含糖食物或口服/静脉推注20g葡萄糖予以纠正，若15~20min后症状仍不能缓解或血浆葡萄糖水平仍很低可以重复给予葡萄糖。对于发生严重低血糖事件的患者，尤其格列本脲所致者，需在静脉推注葡萄糖后给予较长时间(24~72h)的葡萄糖静脉滴注以防止低血糖的再次发生，并至少观察3d，密切监测血糖水平。",
          "start_idx": 0,
          "end_idx": 411,
          "entities": [
            {
              "entity_id": "T526",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T527",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 9,
              "end_idx": 12
            },
            {
              "entity_id": "T528",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51
            },
            {
              "entity_id": "T529",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 61
            },
            {
              "entity_id": "T530",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 65,
              "end_idx": 68
            },
            {
              "entity_id": "T531",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 87,
              "end_idx": 90
            },
            {
              "entity_id": "T532",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 103
            },
            {
              "entity_id": "T533",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108
            },
            {
              "entity_id": "T534",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 132,
              "end_idx": 134
            },
            {
              "entity_id": "T535",
              "entity": "腹泻",
              "entity_type": "ADE",
              "start_idx": 172,
              "end_idx": 174
            },
            {
              "entity_id": "T536",
              "entity": "呕吐",
              "entity_type": "ADE",
              "start_idx": 175,
              "end_idx": 177
            },
            {
              "entity_id": "T537",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 213,
              "end_idx": 216
            },
            {
              "entity_id": "T538",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 253,
              "end_idx": 256
            },
            {
              "entity_id": "T539",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 269,
              "end_idx": 271
            },
            {
              "entity_id": "T540",
              "entity": "静脉推注",
              "entity_type": "Method",
              "start_idx": 272,
              "end_idx": 276
            },
            {
              "entity_id": "T541",
              "entity": "20g",
              "entity_type": "Amount",
              "start_idx": 276,
              "end_idx": 279
            },
            {
              "entity_id": "T542",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 282
            },
            {
              "entity_id": "T543",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 321,
              "end_idx": 324
            },
            {
              "entity_id": "T544",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 331,
              "end_idx": 334
            },
            {
              "entity_id": "T545",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 342,
              "end_idx": 346
            },
            {
              "entity_id": "T546",
              "entity": "静脉推注",
              "entity_type": "Method",
              "start_idx": 352,
              "end_idx": 356
            },
            {
              "entity_id": "T547",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 356,
              "end_idx": 359
            },
            {
              "entity_id": "T548",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 375,
              "end_idx": 378
            },
            {
              "entity_id": "T549",
              "entity": "静脉滴注",
              "entity_type": "Method",
              "start_idx": 378,
              "end_idx": 382
            },
            {
              "entity_id": "T550",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 385,
              "end_idx": 388
            },
            {
              "entity_id": "T551",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 406,
              "end_idx": 408
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R196",
              "head_entity_id": "T527",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R197",
              "head_entity_id": "T535",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R198",
              "head_entity_id": "T536",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R199",
              "head_entity_id": "T537",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R200",
              "head_entity_id": "T538",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R201",
              "head_entity_id": "T534",
              "tail_entity_id": "T528"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R202",
              "head_entity_id": "T530",
              "tail_entity_id": "T529"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R203",
              "head_entity_id": "T531",
              "tail_entity_id": "T532"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R204",
              "head_entity_id": "T531",
              "tail_entity_id": "T533"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R205",
              "head_entity_id": "T539",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R206",
              "head_entity_id": "T540",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R207",
              "head_entity_id": "T541",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R208",
              "head_entity_id": "T544",
              "tail_entity_id": "T545"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R209",
              "head_entity_id": "T550",
              "tail_entity_id": "T545"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R210",
              "head_entity_id": "T546",
              "tail_entity_id": "T547"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R211",
              "head_entity_id": "T549",
              "tail_entity_id": "T548"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "5",
      "paragraph": "2013年版《中国2型糖尿病防治指南》推荐磺脲类药物为重要的一线备选和二线降糖药物，可作为二甲双胍不耐受或存在禁忌证者的起始治疗或二甲双胍治疗血糖控制不佳时的联合用药之一。2014年国际糖尿病联盟(International Diabetes Federation，IDF)全球T2DM指南同样将磺脲类药物作为不适合二甲双胍治疗的患者的一线备选和二线首选药物。2016年美国临床内分泌医师协会(American Association of Clinical Endocrinologists，AACE)和美国内分泌学会(American College of Endocrinology，ACE)指南将磺脲类药物列为T2DM的一线治疗药物之一，但给予谨慎使用的标识。2016年美国糖尿病学会(American Diabetes Association，ADA)指南则推荐磺脲类药物为T2DM患者二甲双胍治疗后的二线药物。因此，磺脲类药物目前仍是临床上治疗T2DM的常用口服药物之一，具有相当重要的临床地位。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2013年版《中国2型糖尿病防治指南》推荐磺脲类药物为重要的一线备选和二线降糖药物，可作为二甲双胍不耐受或存在禁忌证者的起始治疗或二甲双胍治疗血糖控制不佳时的联合用药之一。2014年国际糖尿病联盟(International Diabetes Federation，IDF)全球T2DM指南同样将磺脲类药物作为不适合二甲双胍治疗的患者的一线备选和二线首选药物。2016年美国临床内分泌医师协会(American Association of Clinical Endocrinologists，AACE)和美国内分泌学会(American College of Endocrinology，ACE)指南将磺脲类药物列为T2DM的一线治疗药物之一，但给予谨慎使用的标识。2016年美国糖尿病学会(American Diabetes Association，ADA)指南则推荐磺脲类药物为T2DM患者二甲双胍治疗后的二线药物。因此，磺脲类药物目前仍是临床上治疗T2DM的常用口服药物之一，具有相当重要的临床地位。",
          "start_idx": 0,
          "end_idx": 454,
          "entities": [
            {
              "entity_id": "T552",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 26
            },
            {
              "entity_id": "T553",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 49
            },
            {
              "entity_id": "T554",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T555",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 148,
              "end_idx": 153
            },
            {
              "entity_id": "T556",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 162
            },
            {
              "entity_id": "T557",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 302,
              "end_idx": 307
            },
            {
              "entity_id": "T558",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 386,
              "end_idx": 391
            },
            {
              "entity_id": "T559",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 398,
              "end_idx": 402
            },
            {
              "entity_id": "T560",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 414,
              "end_idx": 419
            },
            {
              "entity_id": "T561",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14
            },
            {
              "entity_id": "T562",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 93,
              "end_idx": 96
            },
            {
              "entity_id": "T563",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 341,
              "end_idx": 344
            },
            {
              "entity_id": "T564",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 9,
              "end_idx": 11
            },
            {
              "entity_id": "T565",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 73
            },
            {
              "entity_id": "T566",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 435,
              "end_idx": 437
            },
            {
              "entity_id": "T567",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 139,
              "end_idx": 141
            },
            {
              "entity_id": "T568",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 143
            },
            {
              "entity_id": "T569",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 309,
              "end_idx": 311
            },
            {
              "entity_id": "T570",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 309,
              "end_idx": 313
            },
            {
              "entity_id": "T571",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 428,
              "end_idx": 430
            },
            {
              "entity_id": "T572",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 428,
              "end_idx": 432
            },
            {
              "entity_id": "T573",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 392,
              "end_idx": 394
            },
            {
              "entity_id": "T574",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 392,
              "end_idx": 396
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R212",
              "head_entity_id": "T552",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R213",
              "head_entity_id": "T553",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R214",
              "head_entity_id": "T554",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R215",
              "head_entity_id": "T555",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R216",
              "head_entity_id": "T557",
              "tail_entity_id": "T570"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R217",
              "head_entity_id": "T558",
              "tail_entity_id": "T574"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R218",
              "head_entity_id": "T559",
              "tail_entity_id": "T574"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R219",
              "head_entity_id": "T560",
              "tail_entity_id": "T572"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R220",
              "head_entity_id": "T566",
              "tail_entity_id": "T560"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R221",
              "head_entity_id": "T564",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R222",
              "head_entity_id": "T565",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R223",
              "head_entity_id": "T569",
              "tail_entity_id": "T570"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R224",
              "head_entity_id": "T573",
              "tail_entity_id": "T574"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "1",
      "paragraph": "磺脲类药物仍是目前糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病(type 2 diabetes mellitus，T2DM)指南中占据着非常重要的治疗地位。长期的临床应用和大量的循证医学证据均表明，磺脲类药物不仅降糖作用强，还可减少或延缓T2DM慢性并发症的发生，特别是微血管并发症。不同磺脲类药物的分子结构、药代/药效动力学以及剂型存在差异，其疗效和安全性也有所不同。为进一步提高临床医生对磺脲类药物的认识，更好地指导临床合理用药，内分泌专家基于循证医学证据的进展，对2004年版《磺脲类药物临床应用专家共识》进行了更新。新版共识采用问答的形式阐明了当前磺脲类药物的临床地位、作用机制、疗效、安全性以及特殊人群用药等问题。主要推荐意见见表1。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物仍是目前糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病(type 2 diabetes mellitus，T2DM)指南中占据着非常重要的治疗地位。长期的临床应用和大量的循证医学证据均表明，磺脲类药物不仅降糖作用强，还可减少或延缓T2DM慢性并发症的发生，特别是微血管并发症。",
          "start_idx": 0,
          "end_idx": 154,
          "entities": [
            {
              "entity_id": "T575",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12
            },
            {
              "entity_id": "T576",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T577",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 116
            },
            {
              "entity_id": "T581",
              "entity": "微血管并发症",
              "entity_type": "Disease",
              "start_idx": 147,
              "end_idx": 153
            },
            {
              "entity_id": "T582",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 147,
              "end_idx": 150
            },
            {
              "entity_id": "T584",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 131,
              "end_idx": 133
            },
            {
              "entity_id": "T585",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 135
            },
            {
              "entity_id": "T586",
              "entity": "2型糖尿病(type 2 diabetes mellitus，T2DM)",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 74
            },
            {
              "entity_id": "T587",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 38,
              "end_idx": 40
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R225",
              "head_entity_id": "T576",
              "tail_entity_id": "T575"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R226",
              "head_entity_id": "T577",
              "tail_entity_id": "T585"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R227",
              "head_entity_id": "T582",
              "tail_entity_id": "T581"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R228",
              "head_entity_id": "T584",
              "tail_entity_id": "T585"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R229",
              "head_entity_id": "T587",
              "tail_entity_id": "T586"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "不同磺脲类药物的分子结构、药代/药效动力学以及剂型存在差异，其疗效和安全性也有所不同。",
          "start_idx": 154,
          "end_idx": 197,
          "entities": [
            {
              "entity_id": "T578",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "为进一步提高临床医生对磺脲类药物的认识，更好地指导临床合理用药，内分泌专家基于循证医学证据的进展，对2004年版《磺脲类药物临床应用专家共识》进行了更新。",
          "start_idx": 197,
          "end_idx": 274,
          "entities": [
            {
              "entity_id": "T579",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 16
            },
            {
              "entity_id": "T583",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 62
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "新版共识采用问答的形式阐明了当前磺脲类药物的临床地位、作用机制、疗效、安全性以及特殊人群用药等问题。",
          "start_idx": 274,
          "end_idx": 324,
          "entities": [
            {
              "entity_id": "T580",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 21
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "4",
          "sentence": "主要推荐意见见表1。",
          "start_idx": 324,
          "end_idx": 334,
          "entities": [],
          "relations": []
        }
      ]
    }
  ]
}